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Abstract  
RNA  is  growing  in  its  importance  as  a  drug  target  and  new  approaches  are  needed  
in   order   to   efficiently   screen   small  molecules   that   bind   and  modulate   the   function   of  
RNA.  Targeting  RNA  with  small  molecules  opens  a  door  to  the  therapeutics  of  diseases  
that   have   not   been   approachable   by   targeting   proteins   and   can   also   increase   the  
effectiveness   of   existing   treatments.   In   the   present   thesis,  we   used   experimental   high  
throughput  screening  utilizing  a  fluorescence-­‐‑based  displacement  assay  and  ensemble-­‐‑
targeted  virtual   screening   to   screen  a   library  of   ~100,000   small  molecules   in   search  of  
compounds  that  inhibit  the  interaction  between  the  transactivation  response  element  of  
HIV-­‐‑1   (TAR)  and  the  Tat  protein,  a  viral  RNA-­‐‑protein  complex   that   is   responsible   for  
the  transcription  elongation.  We  showed  that  dimethyl  sulfoxide  (DMSO),  a  commonly  
used   solvent   to   prepare   small   molecules   for   biochemical   assays,   has   a   small   but  
significant  effect  on  RNA  structure  and  RNA-­‐‑ligand  binding  that  involves  local  melting  
of   base-­‐‑pairs   near   non-­‐‑canonical  motifs.   The   experimental   and   computational   screens  
yielded   complimentary   small   molecule   hits,   which   includes   11   compounds   with   <+2  
formal  charge  at  neutral  pH,  average  molecular  weight  of  480  g/mol,  and  IC50s  ranging  
between  30  µM  and  178  µM.  One  of  the  compounds  showed  significant  transcriptional  
inhibition   in   cell-­‐‑based   assays   utilizing   TZM-­‐‑bl   reporter   cell   lines.   Finally,   we  
characterized  a  transient  state  structure  of  HIV-­‐‑1  TAR  using  NMR  relaxation  dispersion  
experiment  and  mutagenesis  that  simultaneously  modifies  both  a  bulge  and  apical  loop  
   x  
motif   that  are  separated  by  four  base-­‐‑pairs.  This  transient  structure  provides  the  basis  
for   long-­‐‑range   communication   between   remotely   positioned   motifs   and   represents   a  
new  TAR  target  for  developing  ant-­‐‑HIV  therapeutics.  The  combination  of  experimental  
and  virtual  screening  provides  a  general  strategy  for  rapidly  and  effectively  screening  
broad  regions  of  chemical  space  in  search  of  compounds  that  bind  RNA  and  modulate  






1.1 RNA  Dynamics  in  Biology  
Ever  since  the  discovery  of  transfer  RNA  (tRNA)  (1-­‐‑3),  the  first  non-­‐‑coding  RNA  
that  departed  from  being  a  mere  template  for  protein  synthesis,  myriad  of  non-­‐‑coding  
RNAs   has   been   discovered   and   understood   to   be   involved   in   the   regulation   of  
RNA/DNA  modifications  (4),  gene  silencing  (5,  6),  transcription  (7,  8)  and  translation  (7).  
For  example,  HOTAIR  (9)  (HOX  antisense  intergenic  RNA)  is  a  long  non-­‐‑coding  RNA  
that   regulates   the   gene   expression.   It   is   particularly   important   for   epigenetic  
differentiation  of  skin  in  different  parts  of  the  body,  and  the  overexpression  of  HOTAIR  
is   an   indicator   of   metastasis   in   breast   cancer   (10).   MicroRNAs   and   small   interfering  
RNA  (siRNA)  are  known  to  selectively  silence  the  expression  of  genes  by  cleaving  the  
complementary   strand   in   the   gene   or   by   forming   mismatches   that   blocks   the  
transcription  of  the  genomic  RNA  (6).  Varying  sizes,  from  as  small  as  ~20  nucleotides  to  
as  large  as  few  kilobases,  the  non-­‐‑coding  RNAs  (Table  1.1)  participate  in  many  cellular  
processes  and  are  linked  to  diseases  (11,  12).    
Type   Associated  Function  
Messenger  RNA  (mRNA)   Codes  for  protein  
Ribosomal  RNA  (rRNA)   Translation  
Y  RNA   RNA  processing;  DNA  replication  
Telomerase  RNA   Telomerase  synthesis  
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Antisense  RNA  (aRNA)   Gene  regulation  
CRISPR  RNA  (crRNA)  
Immune  system;  protects  from  
parasites  
Long  noncoding  RNA  (lncRNA)   Varius  functions  
MicroRNA  (miRNA)   Gene  regulation  
Piwi-­‐‑interacting  RNA  (piRNA)   Gene  silencing  
Small  interfering  RNA  (siRNA)   Gene  regulation  
7SK  RNA  (7SK)   Transcription  control  
Signal  recognition  particle  RNA  (SRP  RNA)   Protein  trafficking  
Transfer  RNA  (tRNA)   Translation  
Small  nuclear  RNA  (snRNA)   Splicing  
Small  nucleolar  RNA  (snoRNA)   RNA  nucleotide  modification  
SmY  RNA  (SmY)   Splicing  
Guide  RNA  (gRNA)   RNA  nucleotide  modification  
Ribonuclease  P  (Rnase  P)   tRNA  maturation  
Ribonuclease  MRP  (Rnase  MRP)   rRNA  maturation,  DNA  replication  
Circular  RNA  (CircRNA)   Gene  regulation  
Table  1.1  List  of  functional  non-­‐‑coding  RNAs  (11,  12)  
Many  of  the  newly  discovered  non-­‐‑coding  RNAs  have  functions  that  require  large  
changes  from  their  native  conformation  (13-­‐‑16).  These  RNA  conformational  transitions  
take  place  in  response  to  various  cellular  cues  such  as  changes  in  pH  and  temperature,  
and   binding   to   ligands   (e.g.   metabolites),   proteins,   and   RNAs   (13,   17-­‐‑23).   RNA  
conformational  changes  can  involve  re-­‐‑arrangements  in  secondary  structure  that  expose  
or   sequester   key   functional   elements(24-­‐‑26);   formation/  disruption  of   tertiary   contacts  
that  stabilize  functional  3D  structure(27,  28);  and  rapid  librations  of  unpaired  residues  
that  drive  conformational  changes  during  adaptive  recognition(21)  (29,  30).    
3  
  
A   well-­‐‑described   class   of   dynamic   regulatory   RNAs   are   riboswitches   which  
represent  ~50%  of  RNA  structures  solved  to-­‐‑date   (24-­‐‑26).  The  riboswitches  are  mainly  
found   in   prokaryotes,   regulating   gene   expressions,   thus   are   promising   targets   for  
development   of   antibiotics   (24,   25,   31).   Riboswitches   are   composed   of   an   aptamer  
domain  where  a  metabolite  binds  and  consequently  generating  an  expression  platform.  
Binding  of   a  metabolite   to   the  aptamer  domain  ultimately   induces   the   changes   in   the  
secondary  structure  of  expression  platform  that  facilitate  or  inhibit  the  transcription  or  
the   translation,   thus   modulating   gene   expression   through   modulation   of   RNA  
dynamics  (Figure  1.1).    
  
Figure  1.1  Conformational  changes  in  regulatory  RNAs.  Illustration  of  
transcription/translation  control  by  a  riboswitch  
  
The   assembly   of   RNA-­‐‑protein   complexes   (RNP)   is   also   a   dynamic   process   that  
often   involves   sequential   change   in   RNA   structure   induced   by   successive   protein  






















direct   the   order   of   the   assembly   of   ribonucleoprotein   complexes.   For   example,   the  
transactivation  response  element  (TAR)  (34)  from  human  immunodeficiency  virus  type-­‐‑
1   (HIV-­‐‑1)   interacts   with   a   complex   comprising   of   transactivator   protein,   Tat,   and  
positive   transcription   elongation   factor   b   (P-­‐‑TEFb)   to   promote   the   transcription  
elongation  of  viral  RNA.  The  binding  of  Tat  rearranges  the  helices  of  TAR  from  bent  to  
a  more  linear  conformation  (21).  Consequently  this  permits  for  binding  to  the  positive  
transcription  elongation  factor  b  (PTEF-­‐‑b),  which  is  composed  of  cyclin  T1  (cycT1)  and  
cyclin-­‐‑dependent  kinase  9  (CDK9),  and  hyperphosphorylate  the  RNA  polymerase  II  to  
promote  the  transcription  elongation  (35,  36).  The  conformational  change  of  RNA  is  also  
important  in  ribosome  assembly  (37).  For  example,  the  binding  of  ribosomal  protein  S15  
to   16S   RNA   ribosomal   RNA   re-­‐‑orients   the   helices   of   16S   RNA   that   favors   the  
subsequent  binding  of  ribosomal  protein  S6  and  S18  (38).    
  
1.2 Non-­‐‑coding  RNA  and  Disease  
A   growing   number   of   regulatory   RNA   elements   are   being   linked   to   disease  
states,   the   list   including   viral   and   bacterial   infections,   cancer,   genetic   disorders,   and  
neurodegenerative   diseases   (39-­‐‑41)   (Table   1.2).   RNA   viruses   have   non-­‐‑coding   RNA  
elements   in   the  5’-­‐‑  or  3’-­‐‑ends  of   their  genomes,   that  are   indispensable   to   the  viral   life  
cycle,   which   offer   novel   targets   for   development   of   anti-­‐‑viral   compounds   (42-­‐‑44).  
Likewise,  many  riboswitches  are  targets  for  developing  antibiotics  (31,  45).  MicroRNAs  
are   deficient   or   overexpressed   in   cancer   cells,   providing   new  biomarkers   to   diagnose  
and   treat   the   tumors   (46,   47).   All   these   non-­‐‑coding   RNA   are   potential   therapeutic  




Non-­‐‑coding  RNA   Affected  function   Disease  
RPS19,  RPS24   ribosome  biogenesis   Diamond-­‐‑Blackfan  anemia  
DMPK  (gain  of  function)   protein  kinase   Myotonic  dystrophy,  type  1  
ZNF9  (gain  of  function)   RNA  binding   Myotonic  dystrophy,  type  2  
JPH3  (gain  of  function)   ion  channel  function   Huntington'ʹs  disease-­‐‑like  2  
FMR1   translation   Fragile  X  syndrome  
TARDBP   splicing,  transcription  
Amyotrophic  lateral  
sclerosis  
ELF2AK3   translation  (protease)   Wolcott-­‐‑Rallison  syndrome  
miR-­‐‑17-­‐‑92  cluster   RNA  interference   Cancer  
RBM5   splicing   Cancer  







element   viral  transcription   HIV-­‐‑1  
Rev-­‐‑response  element   viral  genome  export   HIV-­‐‑1  
Dimerization  initiation  site   viral  genome  packaging   HIV-­‐‑1  
Table  1.2  Examples  of  diseases  caused  by  non-­‐‑coding  RNA  (31,  41,  42,  48-­‐‑50)    
1.3 Non-­‐‑coding  RNAs  as  a  Drug  Target  
Antibiotics,   such   as   aminoglycosides   (51-­‐‑53),   tetracyclines(54),   macrolides(55),  
and   oxazolidinones(56),   that   target   ribosomal   RNAs   are   the   most   successful   case   of  
RNA-­‐‑targeted   drug   discovery.   These   FDA-­‐‑approved   aminoglycosides,   tetracyclines,  
macrolides,  and  oxazolidinones  bind  16S  ribosomal  A-­‐‑site,  30S  ribosomal  subunit,  P-­‐‑site  
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of   50S   subunit,   and   23S   subunit,   respectively.   The  molecular  mechanism   of   action   of  
these  antibiotics  have  been  unveiled   recently  by  X-­‐‑ray   crystal   structures  of   ribosomes  
(57-­‐‑59)   bound   to   antibiotics   (60-­‐‑62).   For   example,   the   bacterial   16S   ribosomal   A-­‐‑site  
decodes  the  messenger  RNA  (mRNA)  by  flipping  out  two  adenine  bases  in  its  internal  
loop   (63,   64).   These   flipped   out   bases   stabilize   the   nearby   codon-­‐‑anticodon   helix,  
formed   between   the   aminoacyl   tRNA   and   the   mRNA,   facilitating   the   correct  
incorporation   of   amino   acids   by   a   ribosome   (Figure   1.2A).  X-­‐‑ray   crystallography   and  
NMR  studies  (51,  65-­‐‑67)  revealed  that  the  binding  of  an  antibiotic,  paromomycin,  to  the  
16S   ribosomal  A-­‐‑site   induces   the   flipping   of   adenine   bases   (A1492   and  A1493)   in   the  
absence   of   the   correct   codon-­‐‑anticodon   helix   (Figure   1.2B),   resulting   in   a  
misincorporation   of   amino   acids   which   eventually   kills   a   bacteria.   Since   then,   high  
throughput  assays   targeting   the  16S   ribosomal  A-­‐‑site   (68,  69)  have  been  developed   to  
discover  novel  antibiotics.  Moreover,  the  success  of  targeting  ribosomal  RNA  motivated  
targeting  other  regulatory  RNA  elements  including  various  repeats,  riboswitches,  viral  




Figure   1.2.   Mechanisms   of   antibiotics   targeting   16S   ribosomal   A-­‐‑site   RNA.   A.  
Mechanism  of  paromomycin  B.   X-­‐‑ray   crystal   structure   of   paromomycin-­‐‑bound  A-­‐‑site  
RNA.  (PDB:  1J7T)  
  
Riboswitches   are   emerging   as   a   promising   anti-­‐‑bacterial   target   that   potentially  
will  broaden  the  chemical  spectrum  of  antibiotics  to  fight  off  the  bacterial  resistance  (26,  
31,   70).   They   are  mainly   found   in   bacterial   mRNA   and   have   a   well-­‐‑defined   binding  
pocket  for  a  small  metabolite  in  the  aptamer  domain,  providing  a  nice  pre-­‐‑requisite  for  
selective   small  molecule   inhibitors.  Currently,   several  historically  known  antibacterial  
compounds  are  suggested  to  be  targeting  riboswitches.  For  example,  pyrithiamine  (71,  
72),  an  analogue  of  thiamine,  inhibits  the  growth  of  bacteria  and  fungi.  It  was  recently  
shown   that   pyrithiamine   is   readily   phosphorylated   in   cells   to   become   pyrithiamine  
pyrophosphate   (73),  which  binds   to   the  TPP   riboswitch   in  vitro   (74,  75).  Other   similar  
cases  exist  such  as  for  a   lysine-­‐‑analogue,  L-­‐‑aminoethylcystein  (76)  and  DL-­‐‑4-­‐‑oxalysine  
(77)   binding   to   lysine   riboswitch   (45)   and   for   riboflavin-­‐‑analogue,   roseoflavin   (78),  
binding   to   flavin   mononucleotide   (FMN)   riboswitch   (79).   Certain   riboswitches,   for  
example   glucosamine-­‐‑6-­‐‑phosphate   riboswitch   (80),   are   ribozymes   in   the   presence   of  


































































small   molecule   inhibitors.   Two   assays   have   been   developed   utilizing   Fluorescence  
Polarization  (FP)  (81)  and  fluorescence/Förster  Resonance  Energy  Transfer  (FRET)  (82).   
Mutations  in  certain  alleles  can  result  in  inducing  functionality  for  a  RNA  that  is  
overexpressed  and  pathogenic.  For   example,  myotonic  dystrophy   type  1   is   caused  by  
the  overexpression  of  CUG  repeats   (83,  84)   from  50   to  2500   repeats   in  3’-­‐‑untranslated  
region   (UTR)   of   dystrophia   myotonia   protein   kinase   (DMPK)   mRNA.   The  
overexpression   of   CUG   repeats   sequesters   CUG   binding   protein   1   (CUGBP1)   and  
muscleblind-­‐‑like   1   (MBNL1)   proteins   that   results   in   the   abnormal   MBNL1-­‐‑sensitive  
splicing  events  (85,  86)  due  to  accumulation  of  MBNL1  proteins  in  the  nuclear  foci  and  
down  regulation  of  DMPK  mRNA  translation.  Recently,  Disney,  M.  D.  and  co-­‐‑workers  
designed  small  molecules  using  the  multivalency  theorem  (87-­‐‑90)  (Figure  1.3),  linking  2  
-­‐‑   5   weakly   binding   chemical   moieties   to   increase   the   overall   binding   affinity   to   the  
target.  The  small  molecule  inhibitor  bound  to  CUG  repeats  with  Kd  ranging  from  13  nM  
to  100  nM  and  was   shown   to  alleviate   the   splicing  defects  and   increase   translation  of  
DMPK  mRNA  (89).  This  strategy  of  optimizing  small  molecules  using  the  multivalency  




Figure   1.3   Targeting   RNA   repeats   by   a   small   molecule.   A   strategy   to   target   CUG  
repeats  by  a  multivalent  ligand.  An  example  multivalent  ligand  that  binds  CUG  repeats  
is  shown.    
  
HIV-­‐‑1  TAR  is  an  example  of  a  viral  non-­‐‑conding  RNA  drug  target  (34,  42).  The  
current  Highly  Active  AntiRetroviral  Therapy   (HAART)   treatment  program   is  mainly  
composed   of   reverse   transcriptase   inhibitors,   protease   inhibitors,   and   integrase  
inhibitors.   The   challenges   of  HAART   treatment   is   that   the  HIV-­‐‑1   strains   rapidly  gain  
resistance  to  the  drugs,  and  the  treatment  plan  currently  is  to  change  different  drugs  at  
regular   intervals   that   pose   a   high   risk   of   potential   side-­‐‑effects   for   the   various   drugs  
employed.  In  addition,  the  treatment  has  to  continue  on  a  long-­‐‑term  basis,  as  the  latent  
viral   population   remains   unaffected   by   the   treatment   and   these   dormant   viruses   are  
activated  once  the  treatment  stops  (91,  92).  HIV-­‐‑1  TAR  is  an  attractive  therapeutic  target  
as  it  participates  in  several  steps  in  HIV-­‐‑1  life  cycle  including  transcription  (36,  93-­‐‑95),  
translation   (96,   97),   dimerization   (98,   99),   packaging   (98,   100),   and   even   viral   latency  
(101,  102).    
HIV-­‐‑1  TAR  is  located  5’-­‐‑UTR  of  viral  RNA  and  it  is  the  first  element  transcribed  









































































(Tat),  the  P-­‐‑TEFb  complex  is  recruited  (104)  and  stimulates  the  elongation  of  viral  RNA  
by  hyperphosphorylating  the  RNA  polymerase  II  (93,  105)  (Figure  1.4A).  Targeting  TAR  
with  small  molecules  has  been   focused  on   interfering  TAR-­‐‑Tat   interaction.   Interfering  
Tat   and  P-­‐‑TEFb  complex   instead   is  more   challenging  due   to   the   large  protein-­‐‑protein  
interaction   area(106).   So   far   approximately   ~120   small   molecules   with   14   unique  
chemotypes   including   quinolone   derivatives(107-­‐‑110),   polyamidoamines   (111,   112),  
arginine-­‐‑aminoglycoside  conjugates  (113,  114),  and  peptoids  (115,  116),  were  discovered  
to   inhibit   TAR-­‐‑Tat   interactions   with   IC50   between   22   nM   and   1.2   mM.   Only   two  
compounds  were  potent   enough   to  proceed   to   the   animal   studies   (117)   (Figure   1.4B),  
but  unfortunately  none  of   them  have  reached  to   the  clinical   trials.  Nevertheless,   these  
studies  suggest  that  there  is  high  potential  to  target  HIV-­‐‑1  TAR  with  small  molecules.    
  
Figure  1.4  Tat-­‐‑mediated  transactivation  in  HIV-­‐‑1  RNA.  A.  Mechanism  of  Tat-­‐‑mediated  
transactivation   involving   TAR.  B.   Secondary   structures   of   TAR   and   the   structures   of  
two  small  molecules  that  showed  activity  in  mice  (117).    
  
MicroRNA  (miRNA)  also  gained  attention  as  novel  therapeutic  targets  for  treating  
cancers.   With   similar   mechanism   to   siRNA,   miRNA   regulate   the   transcription   and  
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microRNAs   are   under-­‐‑expressed   or   over-­‐‑expressed   in   many   cancer   cells   (47).   These  
changes   in   the   expression   levels   of   miRNA   are   closely   related   to   the   oncogenic   or  
tumor-­‐‑suppressing   activities   and  provide   a   ideal   biomarker   for   cancer  diagnosis   (40).  
For  example,   the   low  expression  level  of  miR-­‐‑122  in   liver  cancer   is   (118)  results   in  the  
down-­‐‑regulation  of  cell’s  apoptotic  pathway  (119).  Recently,  small  molecule  modulators  
of  miRNA  expression  in  cancer  cells  were  discovered  targeting  miR-­‐‑122  for  liver  cancer  
(120).  Interestingly,  the  small  molecules  reverted  the  low  expression  level  of  miR-­‐‑122  in  
liver   cancer  and  re-­‐‑activated   the  apoptosis  of   the  cells.  Similar   reverse  effect  was  also  
observed   for   other   small   molecules   targeting   miR-­‐‑21   (121),   which   is   involved   with  
breast,   ovarian,   and   lung   cancers.   More   recently,   another   study   (122)   showed   that  
combining  the  microarray-­‐‑based  screening  and  ligand-­‐‑based  computational  screening,  a  
small   molecule   was   targeted   specifically   for   inhibiting   the   cleavage   of   miRNA   by  
Drosha  or  Dicer  protein  complexes,  thus  suppressing  the  expression  level  of  miRNAs  in  
cells.      These   studies   indicate   the   promise/potential   of   miRNA   as   a   drug   target   for  
various  types  of  cancer.    
1.4 Principles  for  RNA-­‐‑small  molecule  recognition  
Early   studies   on   the   nature   of   RNA-­‐‑small   molecule   recognition   dating   back   to  
1990s   showed   that   positively   charged   small  molecules,   such   as   aminoglycosides   and  
amino   acid   groups   such   as   lysine   and   arginine   in   proteins,   can   bind   a   variety   of  
regulatory   RNAs   including   16S   ribosomal   RNA,   viral   RNA,   and   ribozymes   and  
modulate  the  cellular  processes.  Soon  after,  NMR  and  X-­‐‑ray  crystal  structures  of  RNA-­‐‑
small   molecule   complexes   provided   detailed   structural   insights   into   RNA-­‐‑small  
molecule   recognition   (21,   65,   123)   (124).   These   studies,   in   addition   to   providing  
structural  insights  of  the  interactions  between  RNA  and  small  molecules,  also  revealed  
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that   RNA-­‐‑small   molecule   recognition   is   often   accompanied   by   significant/substantial  
changes  in  RNA  conformation  referred  to  as  “adaptative  recognition”  (21,  26,  29,  30,  51)  
(Figure  1.5)  
  
Figure  1.5  Examples  of  structural  adaption  by  TAR  upon  binding  of  ligands  (125)  
  
For   example,   the   structure   of   HIV-­‐‑1   TAR   bound   with   argininamide   (21),   an  
analogue   of   arginine,   showed   that   TAR   undergoes   a   large   structural   change   upon  
binding,  resulting  in  a  specific  conformation.  First,  the  global  orientation  of  two  helices  
connected  by  a  trinucleotide  bulge  rearranges  from  a  bent  state  to  a  collinearly  stacked  
state  resulting  due  to  the  change  of  the  inter-­‐‑helical  angle  from  47o  to  ~11o  (21,  126,  127).  
This  global  conformational  change  is  brought  about  by  U23,  the  first  nucleotide  in  the  









































































































of  A27-­‐‑U38  to  interact  with  the  Hoogsteen  interface  of  A27  and  forms  an  A22-­‐‑A27-­‐‑U38  
base   triplet   (21,   128,   129).   This   unique   conformation   of   TAR   allows   argininamide   to  
improve   the   binding   specificity   by   stacking   with   U23   and   forming   hydrogen   bonds  
with  the  phosphate  backbone  of  U23  and  G26  base.  Additional  structural  studies  such  
as  ribosomal  A-­‐‑site  RNA  bound  with  aminoglycosides  (51,  65,  130)  and  ribozymes  (131,  
132),   and   supplementary   biochemical   studies   with   modified   aminoglycosides   (133)  
further   supported   the   importance   of   electrostatics,   hydrogen   bonding   and   stacking  
interactions  in  RNA-­‐‑small  molecule  recognition.  
The   aptamer   domains   of   metabolite-­‐‑sensing   riboswitches   extensively   utilize  
hydrogen   bond   networks   to   bind   ligands   with   exquisite   selectivity   and   affinity.   The  
aptamer   domains   of   riboswitches   are   often   disordered   in   the   absence   of   ligand   but  
assume   intricate   3D   structures   on   adaptive   ligand   recognition,   forming   deep   pockets  
that  engulf  ligands  such  that  that  almost  every  single  atom  of  the  ligand  interacts  with  
the  nucleotides  in  the  riboswitch  via  hydrogen  bonding  or  Van  der  Waals  interactions  
(134).  For  example,  guanine  binds  to  a  guanine  riboswitch,  forming  8  out  of  9  possible  
hydrogen  bonds  directly  with  the  nucleobases  present  in  the  riboswitch  (135,  136).  The  
mutations  of  the  nucleotides  that  form  a  binding  pocket  can  entirely  change  the  binding  
profile  of   the  riboswitch.  For  example,  a  mutant  C74U  guanine  riboswitch  shifts   the  a  
specificity  profile   from  guanine   to  adenine  and  pyrimidine-­‐‑derivatives   (137,  138).   It   is  
also   interesting   to   note   that  merely   increasing   the   number   of   hydrogen   bond   donors  
and   acceptors   in   a   small   molecule   does   not   improve   their   binding   affinity   to   the  
riboswitch   (138).   Thus,   the   specific   positions   of   hydrogen  bond  donors   and   acceptors  
are   important   for   binding   specifically   and   tightly.   Other   than   the   direct   hydrogen  
bonds,   the   indirect   hydrogen   bonds   between   RNA   and   a   small   molecule   via   water  
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molecules   were   also   observed   in   the   small   molecules   bound   to   the   solvent-­‐‑exposed  
binding  pocket,  especially  in  aminoglycoside-­‐‑bound  ribosomal  A-­‐‑site  RNA  (65).    
The  stacking  interactions  also  play  an  important  role  in  small  molecule  binding  to  
RNA   (65,   139).   A   well-­‐‑known   stacking   interaction   is   π-­‐‑π   stacking   interaction   that   is  
common  among  aromatic  compounds  such  as  nucleobases.  It  is  in  fact  the  major  driving  
force   of   the   nucleic   acid   secondary   structure   formation   (140,   141).   The   extensive  
stacking   interactions   observed   in   riboswitches  where   the   binding   site   almost   entirely  
engulfs   the   purine   or   pyrimidine   ligands   (135).   NMR   structure   of   mitoxantrone,   an  
anthracenedione  drug,  bound   to   tau   splicing   regulatory  element   showed  an  extensive  
stacking   of   mitoxantrone   between   base   pairs   of   G17-­‐‑C3   and   C16-­‐‑G1   (139).   Other  
stacking   interactions   such   as   nonionic   stacking   and   cation-­‐‑π   interactions   are   also  
observed  in  glycosidic  groups  and  guanidium  groups,  respectively,  of  small  molecules  
such   as   aminoglycosides   and   argininamide   bound   to   RNA   (21,   65).   The   guanidium  
functional  group  of  arginine  is  one  of  the  most  favorable  RNA  binding  chemotype  with  
5  hydrogen  bond  donors  and  acceptors  and  an  ability  to  stack  with  nucleobases.    
The   electrostatic   interactions   also   play   vital   role   in   small   molecule   binding   to  
RNA.  Due  to  intrinsic  nature  of  negatively  charged  phosphate  groups  in  nucleic  acids,  it  
is   intuitive   to   see   positively   charged   small   molecules   would   favor   binding   to   RNA.  
Indeed,  studies  have  shown  that  aminoglycosides  compete  for  divalent  cation  binding  
to  tRNA  (142)  and  self-­‐‑splicing  group  I  intro  ribozyme  (143,  144).  In  another  study  (133),  
deletion   of   hydroxyl   groups   adjacent   to   the   primary   amine   groups,   to   increase   their  
pKa,   in  aminoglycosides   showed  an   increase   in   their  binding  affinity   to  hammerhead  
ribozyme.  Additional  studies  also  showed  that  the  binding  affinities  of  aminoglycosides  
enhances  with  increase  in  number  of  positively  charged  amine  groups  (131).  Moreover,  
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the  binding  affinities  of  aminoglycosides  diminish  with  increase  in  the  concentration  of  
monovalent   or   divalent   cations   in   a   solution.   A   recent   study   (145)   showed   that   the  
aminoglycosides   with   the   same   number   of   primary   amines   have   different   salt  
dependencies  on  their  binding  affinity.  This  suggests   that   the  electrostatic   interactions  
are   not   non-­‐‑specific   that   merely   depend   on   the   number   of   positive   charges   and  
therefore   can   be   exploited   to   achieve   the   specific   binding   of   small   molecules   by  
positioning  them  appropriately.  
Unlike  B-­‐‑form  DNA  which  forms  a  binding  site  for  a  small  molecule  at  the  major  
and  minor  grooves,  the  RNA  A-­‐‑form  helix  accommodates  small  molecule  binding  less  
favorably(146),  because   the  major  groove   is  narrow  with  width  of   4  Å  and   the  minor  
groove   is  wide  but  exceedingly  shallow  for  small  molecule  binding.  Nevertheless,   the  
RNA  major   groove   is   a   key   site   for   small  molecule   recognition   (146,   147).   The  major  
groove  of  RNA  possesses  more  hydrogen  bond  donors   and  acceptors   than   the  minor  
groove,   and   is   relatively   more   electronegative   than   the   minor   groove   (148).   In   fact,  
many  RNAs  including  tRNA,  group  I  intron,  and  HIV-­‐‑1  TAR  recognize  other  molecules  
via   interactions   at   the  major  groove.  The  presence  of  un-­‐‑paired  nucleotides   that   form  
bulges,   internal   loops,   and   apical   loops   assist   in   perturbing   the   A-­‐‑form   helix   by  
widening   the   major   groove   for   recognition   by   small   molecules,   proteins,   and   other  
RNAs.  This  perturbation  also  results  in  an  electronegative  bias  for  certain  major  grooves  
over   others   creating   “hot   spots”.   These   hot   spots   are   often   observed   to   provide   the  
binding  sites  for  metal  ions  and  small  molecules  and  thus  could  be  exploited  to  guide  
the  rational  design  of  small  molecules  binding  to  RNA  (149).    
1.5 Experimental  Methods  to  target  RNA  
Assays  for  measuring  binding  of  small  molecules  to  RNA    
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   Although   there   are   many   experimental   approaches   that   are   employed   to  
measure   the   binding   affinity   and   inhibitory   activity   of   small   molecules   targeting  
proteins,   developing   assays   for   small   molecule   binding   or   inhibiting   RNA-­‐‑protein  
complexes  is  impeded  due  to  several  reasons.  Firstly,  many  non-­‐‑coding  RNAs  are  non-­‐‑
enzymatic  therefore  cannot  be  assayed  based  on  the  perturbation  of  activity.  Secondly,  
RNA  is  flexible  and  this  often  introduces  challenges  in  labeling  reporters  that  probe  the  
small  molecule  binding.  Nevertheless,  several  assays  have  been  developed  to  probe  the  
RNA-­‐‑ligand  interactions.  
Fluorescence   spectroscopy   is   the   widely   employed   spectroscopic   technique   to  
probe   RNA-­‐‑ligand   interaction   and   to  measure   the   dissociation   constant   (Kd)   of   small  
molecule   binding   to   biomolecules.   Stable   fluorophores   have   been   developed   for  
studying   small   molecule   binding   to   RNA.   Amongst   various   fluorophores,   2-­‐‑
aminopurine  (2-­‐‑AP)  is  the  commonly  used  fluorophore  for  nucleic  acids  assays.  2-­‐‑AP  is  
a   base   analogue   of   adenine   (6-­‐‑aminopurine)   and   it   has   been   demonstrated   to   cause  
minimal   perturbation   to   the   RNA   structure   and   stability   upon   incorporation.   The  
changes   of   fluorescence   intensity   of   2-­‐‑AP   is   predominantly   contributed   by   stacking  
interactions   (150-­‐‑152),   making   it   an   ideal   fluorophore   to   study   the   changes   in   RNA  
secondary   structure   by   fluorescence   spectroscopy.   For   example,   the   argininamide  
binding   of   HIV-­‐‑1   TAR   has   been   studied   with   2-­‐‑AP   labeled   at   C24   or   U25   in   the  
trinucleotide   bulge   region   (153).   The   NMR   studies(21,   154)   have   shown   that   the  
nucleobases  of  the  bulge  residues  C24  and  U25  flip  out  upon  binding  of  argininamide  to  
TAR,   and   as   predicted   the   fluorescence   intensity   of   2-­‐‑AP   labeled   at   C24   or   U25  
increased  upon  binding  (Figure  1.6A).     Similarly,   the  2AP-­‐‑based  assay  was  developed  
for  16S  ribosomal  A-­‐‑site  RNA  (155).  Again,   the  structural  analysis   (63,  65)  of  A-­‐‑site   in  
the   absence   and   the   presence   of   aminoglycosides   showed   that   two   adenine   residues,  
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A92  and  A93,  flipped  out  as  the  aminoglycosides  bound.  As  expected,  substituting  A92  
with   2AP   showed   the   increase   in   the   fluorescence   intensity   upon   binding   of  
paromomycin  (Figure  1.6B).    
  
Figure  1.6  2AP  binding  assay   for  RNA.  A.  Measurement   of   argininamide  binding   to  
TAR  by  2AP  assay.  B.  Measurement  of  paromomycin  binding  to  A-­‐‑site  by  2AP  assay.  
  
Despite   its  great   adaptability   to  RNA  structures,   the  application  of   2-­‐‑AP  based  
fluorescence   assay   precludes   implementation   in   a   high   throughput   mode,   since   the  
excitation   and   emission   wavelengths   of   2-­‐‑AP   lie   in   the   UV   range   resulting   in  
interference  from  any  small  molecule  prospects  that  contain  aromatic  ring  moieties  and  
thereby  restricting  its  application  to  a  limited  chemical  space  of  small  molecules.  Other  
fluorophores  that  mimic  nucleobases  have  been  developed(156),  but  were  not  successful  
in   resolving   the   problem.   Alternatively,   the   fluorescein   is   occassionally   used   as   its  
excitation   and   emission   wavelengths   are   in   the   visible   range   (485nm   to   520nm).  
However,   fluorescein   based   implementation   are   limited   by   the   fact   that   they   can   be  
labeled  only  at  the  terminal  ends  of  RNA,  owing  to  their  bulky  structure,  since  terminal  
ends   are  generally   insensitive   to   small  molecule  binding.  Thus,   the  development  of   a  
novel   fluorophore   that   fluoresces   in   the   visible   light   range   to   study   RNA-­‐‑small  






































































































































   As   an   alternative   to   fluorescence-­‐‑based   assays,   other   techniques   such   as  mass  
spectroscopy   (MS),   nuclear   magnetic   resonance   spectroscopy   (NMR),   isothermal  
calorimetry  (ITC),  surface  plasmon  resonance  (SPR)  and  gel  electrophoresis  have  been  
employed   to   probe   small  molecule   binding   to   RNA   (157-­‐‑160).   Although   they   can   be  
used   to   confirm   the   binding   and   measuring   the   affinity,   however   they   cannot   be  
employed  for  HTS.    
  
High  Throughput  Screening  Targeting  RNA  
  
Figure  1.7  Brief  timeline  of  technical  evolution  in  HTS  (161-­‐‑166).  
  
HTS  is  the  optimal  way  to  explore  the  chemotypes  of  synthetic  compounds  that  
modulate  the  biological  target  of  interest  and  Figure  1.7  shows  a  brief  timeline  of  HTS  
development.   The   origin   of  HTS   is   controversial,   but   Pfizer  was   certainly   one   of   the  
early   adopters   of   HTS   for   natural   product   screening   of   100,000   cloned   DNA   from  
Streptomycetes   in   1984(161).   Using   24-­‐‑well   microplates,   the   researchers   were   able   to  




10,000 extracts / week
1986
Application to small molecule screening
Use of DMSO to solubilize compounds
96-well format
1989
Biochemical and Cell-based assays
10,000 compounds per week
1995
HTS of ADMET tests
1997
First HTS on RNA targets




Evaluation of assay robustness
2006




for   the   natural   product   screening   have   been   implemented   to   the   small   molecule  
screening   by   Pfizer   in   1986,   using   dimethyl   sulfoxide   (DMSO)   to   solubilize   the  
compound   library   (161).   Since   then,   the   HTS   have   been   quite   successful   on   many  
protein  targets  yielding  ~90  drug  candidates  from  HTS  that  are  in  clinical  trials  and  15  
drugs  that  are  approved  for  market(167).      
Despite  the  rapid  development  of  HTS  formats  over  the  last  three  decades  along  
with  many  successes  in  drug  discovery,  proteins  have  remained  the  primary  targets  of  
HTS  and  it  was  only  in  1996  the  first  RNA-­‐‑targeted  HTS  was  published  by  Czarnik,  A.  
W.  and  co-­‐‑workers  (164)  for  two  different  ribozymes,  self-­‐‑splicing  group  I  introns  and  
self-­‐‑assembled   ribozyme.   Using   the   radio-­‐‑labeled   GTP   (α-­‐‑32P-­‐‑labeled   GTP)   and   high  
throughput   filtration   method,   the   small   molecules   that   inhibited   the   GTP-­‐‑mediated  
cleavage  by   the  group   I   introns  were   identified  by  measuring   the   radioactivity  of   the  
cleaved  RNA  products   in  96-­‐‑well  microplates.  Similarly,   the  small  molecule   inhibitors  
of   self-­‐‑assembled   ribozyme  were   identified  using   the   radio-­‐‑labeled   ribozyme.  Among  
the  80  compounds  tested,  2  compounds  showed  >70%  inhibition  of  self-­‐‑splicing  group  I  
introns.   However,   the   size   of   the   chemical   library   was   not   significantly   big   (80  
compounds;  a  single  96-­‐‑well  microplate)  to  be  called  a  HTS.  
A  year  later,  Czarnik,  A.  W.  and  co-­‐‑workers  simultaneously  published  two  HTS  
campaigns   (165,   166)   screening   150,000   small   molecules   against   the   aforementioned  
ribozymes  (self-­‐‑splicing  group  I  intron  and  self-­‐‑assembled  ribozyme)  and  HIV-­‐‑1  TAR-­‐‑
Tat   interaction   being   the   first   non-­‐‑enzymatic   RNA   target   for   HTS   (165).   Using   the  
Scintillation  Proximity  Assay  (SPA)  and  filtration  assay,  150,000  small  molecules  were  
screened  against  HIV-­‐‑1  TAR.  From  the  initial  screen,  3,200  and  2,000  compounds  were  
found  to  be  active  in  SPA  and  2,000  in  filtration  assay.  Subsequent  confirmation  assays  
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for  reproducibility  using  freshly  prepared  compounds  confirmed  one  third  of  the  initial  
hits   as   active   (~500   compounds).   These   500   compounds   were   then   subjected   to   the  
cellular  assays  resulting  in  ~20  non-­‐‑cytotoxic  compounds  with  IC50  <  50  µM.  They  were  
finally   identified  as   inhibitors  of  TAR-­‐‑Tat   interaction   from  the  HTS,  yielding   the   final  
hit  rate  of  0.01%.  It  is  to  be  noted  that  the  molecular  structures  of  these  inhibitors  or  any  
other  hits  from  this  study  were  not  disclosed.  Using  the  aforementioned  assays  (164)  for  
ribozymes,  ~150,000  compounds  were  screened  against  the  self-­‐‑splicing  group  I  introns  
in   96-­‐‑well   microplate   format(166).   Including   the   known   inhibitors   such   as  
aminoglycosides  and  guanosine,  ~1,000  compounds  were  identified  as  hits.  Three  new  
chemotypes  with   IC50s   of   5   –   20  µM  were   identified   from   the   screen.   Since   then,   few  
more  HTS  campaigns  targeted  16S  ribosomal  A-­‐‑site  RNA  (68),  HCV  SL-­‐‑3e  RNA  (168),  
and   HIV-­‐‑1   TAR   (using   different   HTS   assays)   (169),   but   in   general   only   a   few   HTS  
campaigns  for  RNA  are  published  in  the  literature.    
   While   the   technical   advances   boosted   the   screening   throughput,   statistically  
evaluation   of   the   results   from   the  HTS   (reviewed   in   (170))   became   essential.   Z-­‐‑factor  
(163)  is  a  commonly  used  parameter  to  evaluate  the  quality  of  a  HTS  assay  and  is  a  ratio  
between   the   standard   deviations   from   individual   measurements   of   controls   and   the  
dynamic  range  of  the  assay  as  given  in  Eq.  1.    ! = !(!negative!!positive)|!negative!!positive|                             (Eq.  1)  
where   σnegative   and   σpositive   are   standard   deviations   of   fluorescence   intensity   measured  
from  the  negative  and  positive  control  wells,  respectively,  and  Snegative  and  Spositive  are  the  
averaged   value   of   the   signal   intensities   from   negative   and   positive   control   wells,  
respectively.  For  each  plate,  one  or   two  columns   (16-­‐‑32  wells   in  384-­‐‑well  microplates)  
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are  used  for  positive  controls  and  negative  controls,  and  Z-­‐‑factor  is  calculated  for  every  
plate  during  the  HTS  campaign.  The  Z-­‐‑factor  ranges  between  zero  and  one,  with  Z  =  0  
representing  the  least  Z-­‐‑factor  for  an  assay  to  be  considered  in  HTS  setting  while  Z  =  1  
an  ideal  case  with  zero  standard  deviations  of  the  measurements  in  the  assay.  An  assay  
is  deemed  impractical  when  Z  <  0  as  it  reflects  significant  overlap  between  the  standard  
deviations  of  the  positive  controls  and  the  negative  controls.  Typically  for  HTS  a  Z  >  0.5  
is   required   to   characterize   compounds   as   active   or   inactive.      Figure   1.8   shows   the  
simulated  data  points  for  various  cases  of  Z  ranging  between  0  and  1.  
  
Figure   1.8   Simulated   data   points   for   positive   and   negative   controls   in   HTS.   The  
negative   control   wells   and   the   positive   control   wells   are   shown   in   black   and   red,  
respectively.  The  solid  lines  represent  the  mean  of  the  control  wells,  and  the  dotted  lines  
represents  the  3σ  of  the  control  wells  assuming  the  normal  distribution.    
  
1.6 Computational  Docking  to  Target  RNA  
HTS   is   expensive,   time-­‐‑consuming   and   is   often   challenging   when   there   are   no  
suitable  assays  for  examining  binding.  Moreover,  the  cost  to  set  up  the  instruments  for  
HTS  is  extremely  expensive  which  is  the  foremost  reason  why  HTS  is  rarely  performed  
in  academia  until  recently.  As  the  structure  determination  of  proteins  and  nucleic  acids  
by   X-­‐‑ray   crystallography   and   NMR   is   becoming   routine,   computational   docking  
becomes   an   economical   and   viable   alternative   to   HTS.   Computational   docking  
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eliminates   a  need   to   solubilize   the   small  molecule   library   into  DMSO   that   sometimes  
affects   the   structure   and   dynamics   of   biomolecules   (171-­‐‑173).   The   only   constraint   for  
docking  however   is   the  availability  of  high  resolution  3D  structures.  The  structures  of  
small  molecules  are  typically  available  in  many  community-­‐‑based  databases  and  from  
commercial  vendors.  The  computational  docking  can  offer  a  basis  for  guiding  synthesis  
of   novel   RNA-­‐‑targeting   compounds   as   new   small   molecules   can   be   screened   even  
before  they  are  synthetically  available.    
Computational   docking   is   essentially   an   optimization   problem.   The   docking  
program  first  attempts  to  sample  all  possible  ligand  poses  in  the  binding  pocket  of  the  
receptor,  and  evaluates  the  poses  of   the   ligand  using  a  scoring  function  that  describes  
the   various   energy   terms   involved   in   binding,   such   as   hydrogen   bonding,   van   der  
Waals   interactions,   electrostatic   interactions,   and   solvation   energy   of   a   ligand,   for   an  
optimal   ligand   pose.   Computational   docking   can   be   used   to   screen  millions   of   small  
molecules  to  find  a  novel  chemotype  that  binds  to  a  receptor,  namely  virtual  screening  
(VS).   Computational   docking   on   proteins   has   been   quite   successful   resulting   in  
discovering  novel   lead  compounds   targeting   tyrosine  phosphatase   (174),  DNA  gyrase  
(175),  and  HIV  integrase  (176,  177)  that  ultimately  led  to  the  development  of  Raltegravir,  
the   first   FDA-­‐‑approved   antiretroviral   drug   targeting   HIV-­‐‑1   integrase.   However,   the  
computational  docking  against  RNA  has  not  been  quite  as  successful  as  proteins  due  to  
various  challenges  as  discussed.    
One  challenge  of  docking  is  that  it  does  not  account  for  the  flexibility  of  a  receptor,  
which  is  critical  in  the  case  of  RNAs  as  they  are  known  to  be  flexible  as  discussed  in  1.1.  
If   a   receptor   is   flexible,   the   binding   of   small   molecules   can   induce   different  
conformations  of  the  receptor  (Figure  1.5),  and  a  single  static  structure  might  not  be  able  
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to   predict   the   ligand   bound   poses   of   small   molecules,   leading   to   false   positives   or  
negatives.   This   is   particularly   an   issue   when   targeting   RNA   due   to   dramatic  
conformational  changes  that  RNA  undergoes  upon  binding  of  small  molecules  (21,  65,  
125).  To  address  the  receptor  flexibility  problem,  several  schemes,  for  example  docking  
against  multiple  receptor  structures,  have  been  developed  for  proteins  (for  reviews  (178,  
179))  as  well  as  for  RNA  (180-­‐‑182).    
Despite  the  structural  flexibility,  virtual  screens  targeting  RNA  have  been  reported  
showing  some  success  (183-­‐‑185).  Using  DOCK  (186,  187)  and  ICM  (188),  James  and  co-­‐‑
workers  screened  153,000  small  molecules  against  HIV-­‐‑1  TAR  (183).  Among  the  8  best-­‐‑
scored  compounds,  2  compounds  yielded  IC50s  of  1  µM  in  in-­‐‑vitro  scintillation  proximity  
assay.   In   a   subsequent   study   (184),   a   slightly   larger   compound   library   (181,000  
compounds)   was   screened   using   the   same   approach.   Testing   43   top-­‐‑ranked   small  
molecules,   11   compounds  were   confirmed   as   hits   (hit   rate   ~   25%),   one   of  which   also  
exhibited  inhibitory  activity  on  Tat-­‐‑mediated  transactivation  in  vivo.  Other  RNA  targets  
such  as  human  telomerase  RNA  have  also  been  virtually  screened  (189).  
Recently,  Al-­‐‑Hashimi  and  co-­‐‑workers  determined  the  ensemble  of  20  HIV-­‐‑1  TAR  
conformers  from  NMR  and  molecular  dynamics  (MD)  simulations  (190,  191)  capturing  
the  inherent  flexibility  of  the  molecule.  They  showed  that  docking  against  the  ensemble  
of  structures  from  NMR  and  MD  resulted  in  an  improved  prediction  of  small  molecule  
binding   affinities   in   comparison   to   the   predictions   from  docking   against   single   static  
structure  or  NOE  derived  NMR  structures  (181).  In  this  study,  ~51,000  small  molecules  
were  virtually  screened  against  the  20  TAR  conformers  and  58  compounds  from  this  set  
were  experimentally  tested.  Among  these,  7  compounds  were  confirmed  as  hits  (hit  rate  
~12%)   including   spermine,   a   previously   known   binder   and   6   new   inhibitors.   Their  
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binding   and   specificity  were   further   validated   by  NMR   chemical   shift   perturbations,  
fluorescence  binding  assays,  and  cell  assays.  Among  the  hits,  one  compound,  netilmicin,  
was   selective   to   HIV-­‐‑1   TAR   among   other   RNA   therapeutic   targets   and   actively  
inhibited  HIV-­‐‑1  viral  replication  in  cells.    
These  successes  in  virtual  screening  against  RNA  showed  the  great  potential  of  a  
computational  docking  as  a  method  to  explore  the  chemical  space  that  favors  binding  to  
RNA.  However,  a  question  remains  as  to  how  does  the  VS  compared  with  respect  to  the  
experimental  HTS.  Several   studies   (174,  192)   that  screened   library  compounds  against  
protein   targets  have  argued   that   the  HTS  and  VS  are   complementary  methods,   as  VS  
avoids   the   experimental   complications   that  HTS   have   and  HTS   eliminates   the   issues  
related   with   the   accuracy   of   the   binding   affinity   prediction   that   VS   has.   One   of   the  
objectives  of  this  thesis  is  to  investigate  the  specific  issues  arising  from  screening  RNA  
targets   and   evaluate   the   performance   and   complementarity   of  HTS   and   VS  methods  
targeting  RNA.    
1.7 Characterizing  RNA  Dynamic  Structures  as  Potential  Therapeutic  Targets  
RNA  dynamics  play  a  crucial  role   in  regulating  cellular  processes  and  under  the  
effect   of   cellular   cues   RNA   undergoes   various   conformational   changes   that   affect  
various   cellular   processes.   These   effective   conformations   form   transiently   and   are  
encoded  in  the  dynamics  of  RNA  (193-­‐‑198).  These  transient  states  often  occur  at  µs  –  ms  
time  scales  involving  base  opening(199)  and  flipping(197),  sugar  repuckering(198),  and  
ligand   binding(200),   and   they   are   vital   for   biological   functions.   Thus,   characterizing  
these   transient   state  conformations  of  RNA  will  open  a  new  opportunity   to  use  small  
molecules  to  target  the  transient  states  of  RNA.    
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   NMR   spectroscopy   is   a   powerful   tool   not   only   to   determine   3D   structures   at  
atomic  resolution  under  solution  conditions,  but  also  to  characterize  the  dynamics  over  
timescales   ranging   between   picoseconds   (ps)   and   seconds   (s)   (194,   201-­‐‑204).   Various  
NMR  parameters,  such  as  spin  relaxation,  residual  dipolar  coupling,  and  chemical  shifts,  
are  used  to  characterize  the  motions  occurring  at  ps  –  s  time  scale.    In  this  study,  we  use  
rotating   frame   R1ρ   relaxation   dispersion   experiment   (205-­‐‑208)   to   characterize   the  
solution  state  dynamics  of  HIV-­‐‑1  TAR.  The  R1ρ  relaxation  dispersion  experiment  uses  a  
spinlock  field  to  spin  lock  the  magnetization  of  interest  along  an  effective  field  along  or  
tilted  relative  to  the  x-­‐‑y  plane.  One  then  measures  the  R1ρ  relaxation  rates  as  a  function  
of   varying   the   strength   of   the   spinlock   pulse   as   well   as   the   offset   frequency.   The  
limitation  of  the  spinlock  pulse  strengths  determines  the  detection  limit  of  time  scales  in  
R1ρ  relaxation  dispersion.    
   The   conventional   2D   R1ρ   relaxation   dispersion   experiment   was   limited   to  
spinlock   fields   >   1000   Hz,   which   limited   the   R1ρ   relaxation   dispersion   experiment  
capable  of  detecting  motions  slower  than  µs  time  scale.  A  recent  development  in  pulse  
sequence  design  (206)  involving  selective  excitation  of  single  resonances  overcomes  the  
limitations   posed   by   the   spinlock   power   and   makes   it   possible   to   use   much   lower  
spinlock   powers   of   ~25   Hz   in   proteins   and   up   to   100   Hz   in   nucleic   acids   (206,   208)  
alleviating  the  limitation  and  extending  the  detection  limit  up  to  milliseconds.    
   The  R1ρ  relaxation  rate  is  described  mathematically  as  below,  
!1! = !!!"#!! + !!!"#!! + !!"!"#!!                     (Eq.  2)  
! = arctan  (!!Ω )  
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where  R1  and  R2  are  intrinsic  longitudinal  and  transverse  relaxation  rates,  respectively,  
and   Rex   is   the   relaxation   rate   due   to   chemical   exchange.   θ   is   the   effective   tilt   angle,  
where   ω1   is   the   spinlock   power   and   Ω   is   the   offset   of   the   spin   from   the   spinlock  
frequency.  The  chemical  exchange  increases  the  overall  R1ρ  relaxation  rate,  and  one  can  
observe  the  chemical  exchange  term  by  changing  the  spinlock  power  and  the  offset.    
   The   relaxation   rate   due   to   chemical   exchange   (Rex)   can   be   mathematically  
described  by  Bloch-­‐‑McConnell  equation  (209).  Because  Bloch-­‐‑McConnell  equation  is  6x6  
matrix   form,   which   challenges   to   fit   the   experimental   data,   much   simpler  
approximations   to   the   solution   of   Bloch-­‐‑McConnell   equation   are   used   (reviewed   in  
(205)).  One  of  the  important  assumptions  in  the  simplified  equations  is  that  the  intrinsic  
R1  and   R2   are   separable   from  Rex,  which   is   valid   under  most   experimental   conditions  
where  !!!!"   ≪ 1,   !!! − !!! ≪ !!",   !!! − !!! ≪ !!",  and  !! − !! ≪ !!".  The  term  τc  is  
the  correlation  time  of  overall  rotational  diffusion  of  a  molecule,  kex  is  the  exchange  rate  
constant,  and  R1a,  R2a,  R1b,  and  R2b  are  the  individual  relaxation  rates  (R1  and  R2)  of  two  
species   undergoing   chemical   exchange   in   the   simplest   2-­‐‑state   model   of   chemical  
exchange,  
! !!⇌!!!!  
where   k1   is   forward   rate   constant   and   k-­‐‑1   is   backward   rate   constant   of   the   transition  
between  state  A  and  state  B.  The  sum  of  k1  and  k-­‐‑1  yields  the  exchange  rate  constant  (kex).    
   The  most   accurate   approximation   to   the   solution   of   Bloch-­‐‑McConnell   equation  
uses  Laguerre’s  method  for  polynomial  root  finding  (209).  In  the  simple  2-­‐‑state  model,  
the  Laguerre’s  approximation  of  the  relaxation  rate  due  to  chemical  change  is,  
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!!" = !!!!!!!!!"!!!!!! !!!!!!"! !!"#!!!!!!!!!(!!!!!"! !!!!!!!!!!!!!!!!!!!!!!!"! )                                    (eq.  3)  
where   pa   and   pb   are   populations   of   state   A   and   state   B,   Δω2   is   the   chemical   shift  
difference  between  state  A  and  B,  ωa  and  ωb  are  the  effective  magnetization  of  state  A  
and  state  B,  and  ωe  is  the  effective    magnetization  of  the  offset  between  the  state  A  and  
B.   By   fitting   this   equation,   the   chemical   shift   difference   (Δω),   the   population   of   the  
transient  state  (pb)  and  the  exchange  rate  constant  (kex)  can  be  extracted.  There  are  other  
exchange  models   with  more   than   2-­‐‑states(205),   and   F-­‐‑test   and/or   Akaike   test   can   be  
used   to   compare   and   select   the   appropriate  model   that   best   fits   to   the   experimental  
data.    
1.8 Objectives  of  this  Dissertation  
The   objective   of   this   dissertation   is   to   explore   experimental   and   computational  
methods  to  discover  small  molecule  modulators  targeting  HIV-­‐‑1  TAR.  First,  the  effect  of  
DMSO,  a  universal  solvent  used  in  HTS,  is  evaluated  against  RNA  targets  (Chapter  2).  
The  screening  results  from  HTS  and  ensemble-­‐‑based  VS  targeting  HIV-­‐‑1  TAR  and  their  
performances   are   evaluated   (Chapter   3).   The   transient   states   of   HIV-­‐‑1   TAR   are  
characterized   using   NMR   R1ρ   relaxation   dispersion   experiment   (Chapter   4).   These  
transient   states  are  biologically   significant   in   regulatory   functions  of  RNA  and  can  be  
potentially  targeted  by  small  molecules.    
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Influence  of  Dimethylsulfoxide  on  RNA  Structure  and  Ligand  Binding  
2.1 Introduction  
Many   regulatory  RNA   elements   are   emerging   as   new  potential   drug   targets   for  
treating  a  wide  range  of  diseases(1-­‐‑5).  For  example,  riboswitches  are  RNA-­‐‑based  gene  
regulatory  elements  in  bacteria  that  form  complex  3D  structures,  and  are  being  targeted  
in   the   development   of   antibiotics(6-­‐‑8).   Many   RNA   hairpin   structures,   including  
bacterial(9,   10)   and   retroviral   elements(11-­‐‑15),   human   micro-­‐‑RNAs(16),   various  
repeats(17,   18)   as   well   as   more   complex   pseudoknots(19)   are   being   targeted   in   the  
development   of   therapeutics   against   infectious   diseases,   diabetes,   various   genetic  
disorders,   and   cancer.   There   is   growing   interest   in   using   experimental   and  
computational   high   throughput   screens   (HTS)   to   identify   small   molecules   that   can  
target   RNA(2-­‐‑5)   and   that   overcome   delivery   limitations   inherent   to   large   molecular  
weight  RNA-­‐‑based  therapeutics  such  as  antisense(20)  and  small  interfering  RNAs(21).    
Dimethyl  sulfoxide  (DMSO)  is  widely  used  as  a  universal  solvent  in  HTS  due  to  
its   miscibility   with   water,   non-­‐‑reactivity,   and   ability   to   dissolve   hydrophobic  
compounds(22).   Although   it   is   well   established   that   DMSO   concentrations   (<10%)  
typically  used  in  HTS  can  have  a  significant  effect  on  the  stability  of  certain  proteins(22)  
and   reduce   ligand   binding   affinities   by   as   much   as   10-­‐‑fold(23),   few   studies   have  
examined   the   impact   of   DMSO   (<10%)   on   RNA   structure   and   ligand-­‐‑binding.   Such  
studies   are   needed   given   that   many   RNA   targets   are   highly   flexible(24,   25)   and  
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therefore   potentially   highly   susceptible   to   perturbations   by   external   chemical  
agents.(26)   Indeed,  high  DMSO  concentrations   (>75%)  have  previously  been  shown  to  
disrupt  the  structure  and  stability  of  RNA(27,  28)  and  DNA.(29-­‐‑31)  In  particular,  NMR  
studies   of   yeast   tRNAphe   showed   that   high  
concentrations  of  DMSO  (up  to  83%)  resulted  in  
changes   in   the   1H   spectra   that   were   consistent  
with   disruption   of   base-­‐‑stacking   and   increased  
flexibility(28).   Moreover,   in   a   recent   virtual  
screen   targeting   the   transactivation   response  
element   (TAR)   RNA   from   the   human  
immunodeficiency   virus   type   I   (HIV-­‐‑1),   we  
found  that  the  vast  majority  of  false  positive  hits  
were   water   insoluble   compounds   that   required  
DMSO   for   dissolution.(13)   Therefore,   it   is  
important   to   verify   that   DMSO   does   not   affect  
the  structure  of  TAR  and  other  RNAs  or  interfere  
with   their   ability   to   bind   small   molecules   in  
ways   that   are   not   accounted   for   in   the   virtual  
screen.  
Here   we   use   a   combination   of   nuclear   magnetic   resonance   (NMR)   and  
fluorescence   spectroscopy   to   explore   how   DMSO   affects   the   structure   and   ligand-­‐‑
binding  properties  of  two  flexible  hairpin  RNA  structures;  HIV-­‐‑1  TAR  (32,  33)  and  the  
ribosomal  A-­‐‑site(34,  35)  (Figure  2.1).  These  two  RNAs  have  served  as  model  systems  for  
Figure   2.1   Secondary   structure   of  
RNA   used   in   this   study.   Solid   and  
dashed   lines   denote   Watson-­‐‑Crick  
and   flexible   base  pairs,   respectively.  
A.  HIV-­‐‑1  TAR  B.  Bacterial  ribosomal  
A-­‐‑site.  The  open  circle  denotes  a  U-­‐‑U  
wobble  base  pair.  
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understanding  RNA-­‐‑small  molecule  targeting  and  provide  an  excellent  opportunity,  to  
examine  in  depth,  the  impact  of  DMSO  on  RNA  structure  and  ligand  binding.  
  
2.2 Materials  and  Methods  
Preparation  of  RNA  samples  and  small  molecules  
2-­‐‑aminopurine   (2AP)-­‐‑labeled   TAR   and   A-­‐‑site   RNA   were   purchased   from  
Dharmacon   (Lafayette,   CO).   Uniformly   13C/15N   labeled   TAR   RNA   and   A-­‐‑site   RNA  
(Figure   2.1)   were   prepared   by   in   vitro   transcription   using   double   stranded   DNA  
encoding   the   RNA   sequence   of   interest   and   containing   the   T7   promoter   at   5’-­‐‑end  
(Integrated  DNA  Technologies).  T7  RNA  polymerase  (Takara  Mirus  Bio,  Inc.)  was  used  
to   transcribe   the   DNA   sequence   in   the   presence   of   13C/15N   labeled   nucleotide  
triphosphates   (ISOTEC,   Inc.   and  Cambridge   Isotope  Laboratories,   Inc).  The  RNA  was  
purified  using  20%  (w/v)  denaturing  polyacrylamide  gel  electrophoresis  (PAGE)  in  8M  
urea   and   1X   TBE.   The   RNA  was   electroeluted   in   20mM  Tris   (pH   8)   buffer   and   then  
precipitated   in   ethanol.   The   purified   RNA   pellet   was   dissolved   and   exchanged   into  
NMR   buffer   (15mM   sodium   phosphate,   25mM   sodium   chloride,   0.1mM   EDTA,   10%  
(v/v)  D2O,  and  pH  ~  6.4)  using  a  centricon  ultracel  YM-­‐‑3  concentrator  (Millipore  Corp.).  
The  compounds  L-­‐‑argininamide  (A3913),  mitoxantrone  (M6545),  kanamycin  B  (B5264),  
and   paromomycin   (P9297)   were   purchased   from   Sigma-­‐‑Aldrich   (St.   Louis,   MO).   2-­‐‑
aminopurine   base   (276560500)   was   purchased   from   Acros   Organics   (Geel,   Belgium).  




All  NMR  experiments  were  performed  at   298K  on  600  MHz  Avance  Bruker  or  
Agilent   spectrometers   equipped  with   5mm   triple-­‐‑resonance   cryogenic   probe.   5%   and  
10%   DMSO  were   added   volume   by   volume   (v/v).   All   NMR   spectra   were   processed  
using   NMRPipe(36)   and   SPARKY   3(37).   The   overall   chemical   shift   perturbations  
(Δδoverall)  upon   incremental  addition  of  DMSO   in  2D-­‐‑HSQC  spectra  of  TAR  and  A-­‐‑site  
were  calculated  using  the  following  equation:,  
∆δoverall = (∆δ!)! + (!C!H ∆δC )!                        (1)  
where  ΔδH  and  ΔδC  are  the  changes  in  1H  and  13C  chemical  shift  (in  ppm),  respectively,  
and  γH  and  γC  are  gyromagnetic  ratios  for  hydrogen  and  carbon,  respectively.  For  N-­‐‑H  
HSQC   spectra,   γC   and   ΔδC   are   replaced   with   γN   and   ΔδN,   respectively,   which   are  
gyromagnetic   ratio   for   nitrogen   and   the   changes   in   15N   chemical   shift   (in   ppm),  
respectively.    
Fluorescence  Spectroscopy  
The  fluorescence-­‐‑based  binding  assays  employed  TAR  RNA  with  2AP  labeled  at  
the  bulge  residue  U25  (2AP-­‐‑U25-­‐‑TAR)  and  ribosomal  A-­‐‑site  RNA  with  2AP  labeled  at  
the   internal   loop   residue   A92   (2AP-­‐‑A92-­‐‑Asite).   10   µM   of   2AP-­‐‑labeled   RNA   was  
annealed  by  heating  to  95°C  for  5  minutes  and  then  cooled  on  ice  for  an  hour  prior  to  
use.  The  folded  RNA  was  diluted  to  20  nM  concentration  in  assay  buffer  (10mM  sodium  
phosphate,   50mM  NaCl,   0.1mM  EDTA,  and  pH  ~6.8).  The   temperature  of   the   cuvette  
holder  was  maintained  at  25oC  with  a  water-­‐‑cooling  system.  DMSO  was  added  volume  
by   volume   (v/v).   Time-­‐‑resolved   fluorescence   intensity   measurements   were   collected  
using  a  Fluoromax-­‐‑2  fluorimeter  at  320  nm  excitation  and  370  nm  emission  wavelengths  
following   incremental   addition   of   small   molecules   in   1:1000   dilutions.   Each   titration  
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point   with   small   molecule   was   averaged   over   15   seconds   of   fluorescence   intensity  
measurement   with   0.1   second   time   interval.   The   slit   width   was   10   nm.   All  
measurements  were  triplicated.  The  fluorescence  emission  intensities  were  normalized  
with   respect   to   the   fluorescence   emission   intensity   in   the   absence  of   small  molecules.  
With   the   exception   of   kanamycin   B   binding   to   TAR,   all   dissociation   constants   were  
computed   by   fitting   to   the   following   equation   using   the  Origin   software   (Origin   Lab  
Corporation),  
  
                                 (eq.  2)
  
where   [RNA]T   is   the   total   RNA   concentration,   [L]T   is   the   total   small   molecule  
concentration,   and   A   and   B   are   fluorescence   contribution   factors   that   account   for  
relative   fluorescence   intensities   in   the   free   and   bound   state,   respectively(38).   The  
titration   data   for   kanamycin   B   binding   to   TAR   exhibited   two   inflection   points  
characteristic  of  two-­‐‑site  binding.  This  data  did  not  fit  well  to  Equation  2  (reduced  χ2  ~  
44)   and   was   instead   fitted   to   Equation   3   (reduced   χ2   ~   0.2)   which   assumes   two  
independent  site  binding:  
  
(eq.  3)  
F = A![RNA]T +B!
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The   lower  affinity  binding  site   is  not  observed  under  higher   ionic  strength  conditions  
(150mM  NaCl  or  3mM  MgCl2)  and  therefore   likely  reflects  non-­‐‑specific  binding  to  the  
RNA.    
The   fluorescence   emission   spectra   of   2AP-­‐‑U25-­‐‑TAR,   2AP-­‐‑A92-­‐‑Asite,   and   2-­‐‑
aminopurine   base   were   measured   using   Fluoromax-­‐‑2   fluorimeter   in   the   same   assay  
buffer  used   in   the  binding  assays.  The   fluorescence  emission  was  measured   from  350  
nm  to  400  nm  with  excitation  at  320  nm.  All  spectra  were  averaged  over  3  scans.    
2.3 Results  and  Discussion  
Impact  of  DMSO  on  the  structure  and  dynamics  of  RNA  by  NMR  
We   investigated   how  DMSO   affects   the   structure   of  HIV-­‐‑1   TAR   (Figure   2.1A)  
and  bacterial  ribosomal  A-­‐‑site  RNA  (Figure  2.1B)  using  NMR  chemical  shift  titrations,  
where  we  acquired  2D  N-­‐‑H  and  C-­‐‑H  HSQC  spectra  of  uniformly  13C/15N  labeled  RNA  
following   the   incremental   addition   of   DMSO   up   to   10%   concentration,   which  
corresponds  to  the  higher  end  of  DMSO  concentrations  typically  used  in  ligand-­‐‑binding  
assays.(39)    
Increasing  concentrations  of  DMSO  resulted  in  specific  perturbations  in  the  TAR  
chemical   shifts   at   residues   located   in   and   around   the   flexible   bulge   and   apical   loop  
(Figure  2.2A).  This  data   suggests   that  DMSO  affected   the  TAR  conformation  and   that  
the  transition  between  free  and  “DMSO-­‐‑bound”  TAR  occurs  in  fast  exchange  relative  to  
the   NMR   timescale.   The   most   significant   (Δδoverall   >   0.1   ppm)   perturbations   were  
observed   for   residues  A22   and  U23   in   and   around  bulge   and   the   apical   loop   residue  






Figure  2.2  Examining  impact  of  DMSO  on  HIV-­‐‑1  TAR  conformation  by  NMR.  A.  2D  
C-­‐‑H  and  N-­‐‑H  HSQC  spectra  of  TAR  in   increasing  DMSO  concentration.  B.  Secondary  
structure   of   highlighting   residues   (in   red   circles)   that   undergo   the   largest   DMSO  
induced  chemical  shift  perturbations  (Δδoverall  >0.1  ppm).  
  
The   downfield   perturbations   in   the   nucleobase   (C6/C8)   carbon   resonances  
induced  by  DMSO  at  the  bulge  (A22(C8H8),  U23(C6H6),  and  U25(C6H6))  suggest  loss  
of   stacking   interactions(42-­‐‑44).   Interestingly,   all   of   the   DMSO-­‐‑induced   chemical   shift  
perturbations  in  and  around  the  bulge,  including  for  A22,  U23,  C24,  U25  and  U40  were  
similar  to  those  induced  by  increasing  Mg2+  and  Na+  concentrations  (Figure  2.3),  which  
were   previously   shown   to   stabilize   a   co-­‐‑axial   TAR   conformation   in   which   all   three  
bulge   residues   are   flipped  out   and   flexible.(45,   46)   Indeed,  DMSO   induced   a   gradual  
increase  in  the  normalized  resonance  intensities(47)  in  the  bulge  resonances  (U23,  C24,  
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U25)   (Figure   2.4),   consistent   with   an   increase   in   picosecond-­‐‑to-­‐‑nanosecond   timescale  
motions  due  to  loss  of  stacking  interactions.    
  
Figure  2.3  Comparison  of  2D  C-­‐‑H  HSQC  spectra  of  HIV-­‐‑1  TAR  in  0-­‐‑10%  DMSO  and  
4mM  MgCl2.  
  
In  contrast,  the  DMSO-­‐‑induced  perturbations  at  apical  loop  residue  A35(C1´H1´)  
were  not  observed  with   increasing  Mg2+   (Figure  2.3)  and   there  were  many  resonances  
which  showed  significant  perturbations  with  Mg2+  that  showed  little  to  no  perturbations  
with  DMSO   (Figure   2.3).   The   carbon   perturbations   for  G34(C8H8),  A35(C1´H1´),   and  
A35(C8H8)   suggest   stabilization   of  A35   in   a   flipped   out   conformation   and  G34   in   an  
intra-­‐‑helical  stacked  conformation.  Prior  studies  have  shown  that  A35  and  G34  exist  in  a  
dynamic  equilibrium  in  which  they  inter-­‐‑change  stacking  interactions,  with  one  residue  
flipping   in  while   the  other   flips  out,  with   the  dominant   form  being  a  conformation   in  
which  A35  is  flipped  out  and  G34  flipped  in(42).     The  NMR  data  suggests  that  DMSO  
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favors  this  dominant  conformation.  This  is  also  consistent  with  the  gradual  increase  in  
measured   normalized   resonance   intensities      (Figure   2.4)   seen   for   A35(C1´H1´)   and  
A35(C8H8)  upon  addition  of  DMSO.    
  
Figure   2.4   Normalized   resonance   intensities   measured   from   2D-­‐‑HSQC   spectra   of  
TAR   as   a   function   of   DMSO   concentration.   Orange   residues   and   green   residues  
belong  to  the  bulge  and  apical  loop  respectively.  The  dotted  line  shows  the  normalized  
intensity  of  A35(C8H8).  
  
In   contrast,   little   to   no   chemical   shift   perturbations   or   changes   in   resonance  
intensities  were  observed   for  more   stable  helical   residues.  This   is  also  consistent  with  
the   imino  N1-­‐‑H1   and  N3-­‐‑H3  HSQC   spectra   (Figure   2.2A),  which   showed   little   to   no  
changes  on  addition  of  DMSO.  Thus,  the  more  stable  helical  residues  seem  to  be  more  
shielded  from  the  effects  of  DMSO.    
Addition   of   DMSO   to   A-­‐‑site   also   resulted   in   significant   chemical   shift  
perturbations,  which  were   localized   in   flexible   internal   loop   (A08,  A92   and  A93)   and  
nearby   residues   (G91   and   G94),   indicating   that   DMSO   also   induced   changes   in   the  
structure   of   A-­‐‑site   (Figure   2.5A).   Once   again,   the   gradual   changes   in   the   NMR  
resonance   positions  with   increasing  DMSO   suggests   that   any   transition   between   free  
and   “DMSO-­‐‑bound”  A-­‐‑site   occurred   in   fast   exchange   relative   to   the  NMR   timescale.  
The   largest  perturbations   (Δδoverall   >  0.1  ppm)  were  observed   for   the   flexible  and   intra-­‐‑
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helically  stacked  A92  (Figure  2.5B).  The  downfield  shifted  13C  chemical  shift  particularly  
for  A92(C8H8)  is  consistent  with  the  loss  of  stacking  and  flipping  out  of  the  adenosine  
base.   Indeed,   similar   perturbations   were   observed   for   A92   upon   the   addition   of   the  
aminoglycoside  paromomycin,  which  has  been  known   to  promote   the   flipping  out  of  
A92.(34,   48,   49)   This   is   also   consistent   with   the   gradual   increase   in   measured  
normalized   resonance   intensities(47)   (Figure   2.6)   for   A92   and   A93   upon   addition   of  
DMSO,  consistent  with  an  increase  in  picosecond-­‐‑to-­‐‑nanosecond  timescale  motions  due  
to  loss  of  stacking  interactions.    
  
Figure  2.5  Examining  impact  of  DMSO  on  bacterial  A-­‐‑site  conformation  by  NMR.  A.  
2D   C-­‐‑H   and   N-­‐‑H   HSQC   spectra   of   A-­‐‑site   in   increasing   DMSO   concentration.   B.  
Secondary   structure   of   A-­‐‑site   highlighting   residues   (in   red   circles)   that   undergo   the  





Figure  2.6.  Normalized  resonance  intensities  measured  from  2D-­‐‑HSQC  spectra  of  A-­‐‑
site  as  a   function  of  DMSO  concentration.  Orange   residues  denote   the   internal   loop  
residues.  The  dotted  line  shows  the  normalized  intensity  of  A92(C8H8).  
  
DMSO   did   not   induce   any   significant   chemical   shift   perturbations   in   the  
thermodynamically  stable  UUCG  apical  loop(50).  However,  in  contrast  to  TAR,  DMSO  
did   have   an   effect   on   the   2D   N-­‐‑H   HSQC   spectrum   of   A-­‐‑site.   In   particular,   DMSO  
induced   a   significant   downfield   shift   in   the   imino   proton   of  G91-­‐‑H1,   suggesting   that  
DMSO  affects   the  C09-­‐‑G91   base-­‐‑pair,  which   is   near   the   non-­‐‑canonical   residues.  Once  
again,  canonical  base-­‐‑pairs  embedded  within  helices  did  not  exhibit  significant  chemical  
shift  perturbations  with  DMSO.    
  
Impact  of  DMSO  on  stacking  interactions  using  2-­‐‑AP  fluorescence    
We   used   2-­‐‑aminopurine   (2AP)   fluorescence   to   further   examine   the   impact   of  
DMSO  on  stacking  interactions.  2AP  is  widely  used  as  a  fluorescent  reporter  of  stacking  
interactions  in  nucleic  acids  since  the  fluorescence  emission  intensity  is  highly  sensitive  
to   the   details   of   the   stacking   interactions,   and   generally   increases   upon   transitioning  
from  a  stacked  to  an  unstacked  conformation.(51-­‐‑53)  For  these  studies,  we  used  a  TAR  
construct  (2AP-­‐‑U25-­‐‑TAR)(38)  in  which  the  flipped  out  bulge  residue  U25  is  labeled  with  
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2-­‐‑AP   and   an  A-­‐‑site   construct   (2AP-­‐‑A92-­‐‑Asite)(54)   in  which  A92   is   labeled  with   2-­‐‑AP  
(Figure   2.7).   Both   of   these   constructs   have   previously   been   used   in   ligand   binding  
studies(38,  54).  
  
Figure   2.7   Examining   impact   of   DMSO   on   RNA   stacking   interactions   using   2AP  
fluorescence.   Shown   is   the   emission   spectrum   of   2AP   at   max   wavelength   with  
increasing  DMSO  concentration  A.  2-­‐‑AP  B.  2AP-­‐‑U25-­‐‑TAR.  C.  2AP-­‐‑A92-­‐‑Asite.  
  
As  a  control,  we  first  examined  how  DMSO  affects  the  fluorescence  intensity  of  
the  2-­‐‑AP  base.  Upon  addition  of  5%  and  10%  DMSO,  we  observed  a  small   increase  in  
the   fluorescence   intensity   of   2-­‐‑aminopurine   base   at   maximum   emission   wavelength  
(λmax  =  378nm)  of  5%  and  11%,  respectively  (Figure  2.7A).  This  indicates  that  DMSO  did  
not   significantly   alter   the   fluorescence  properties   of   2-­‐‑AP.  Moreover,   addition  of   10%  
DMSO  did   not   shift   the  maximum   emission  wavelengths   of   2-­‐‑aminopurine   base   and  
2AP-­‐‑labeled  RNA  constructs.  
Addition  of  5%-­‐‑10%  DMSO  increased  the  fluorescence  intensity  of  2AP-­‐‑U25-­‐‑TAR  
at  maximum  emission  wavelength  (λmax  =  374nm)  by  44%-­‐‑75%  (Figure  2.7B).  For  A-­‐‑site,  
5%-­‐‑10%  DMSO  increased  the  fluorescence  intensity  at  maximum  emission  wavelength  
(λmax  =  370nm)  by  19%  and  32%,  respectively  (Figure  2.7C).  The  observed  increase  in  the  
fluorescence   intensities   is   consistent   with   the   DMSO-­‐‑induced   loss   of   stacking  
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interactions  within  the  TAR  bulge  and  A-­‐‑site  internal  loop,  as  suggested  independently  
by   the   NMR   data.   The   smaller   DMSO-­‐‑induced   increase   in   fluorescence   intensity  
observed   for   A-­‐‑site   as   compared   to   TAR   is   likely   because   the   purine   A92   retains  
stacking  interactions  with  the  flipped  out  A93  as  observed  in  structures  of  A-­‐‑site  bound  
to  aminoglycosides(48,  54).    
Impact  of  DMSO  on  ligand  binding  affinity    
We   used   2-­‐‑AP   fluorescence   to   examine   the   impact   of   DMSO   on   the   binding  
affinity  of  small  molecules  that  bind  to  TAR  and  A-­‐‑site.  We  measured  the  dissociation  
constants   (Kd)   for   argininamide   (ARG)   (Figure   2.8A),   kanamycin  B   (Figure   2.8B),   and  
mitoxantrone   (Figure   2.8C)   binding   to   TAR   and   for   paromomycin   (Figure   2.9A)   and  
mitoxantrone  (Figure  2.9B)  binding  to  A-­‐‑site.  ARG  is  a  ligand  mimic  of  TAR’s  cognate  
protein   target,   the   transactivator   protein,   which   binds   TAR  with  micromolar   affinity  
and   which   has   been   shown   to   recapitulate   many   essential   features   of   TAR-­‐‑Tat  
recognition(55-­‐‑57).  Kanamycin  B  and  paromomycin  are  example  aminoglycosides   that  
bind  RNA  in  the  nanomolar  range  and  in  a  manner  strongly  dependent  on  electrostatic  
interactions.(58-­‐‑61)   Mitoxantrone   is   a   newly   identified   intercalator   that   binds   non-­‐‑




Figure  2.8.  Impact  of  DMSO  on  TAR-­‐‑small  molecule  binding  affinities.  Shown  are  2-­‐‑
AP  fluorescence  intensity  titration  curves  for  small  molecule  binding  to  2AP-­‐‑U25-­‐‑TAR  
with  varying  DMSO  concentration.  A.  Argininamide.  B.  Kanamycin.  C.  Mitoxantrone.  
Error  bars  are  obtained  from  repeating  the  measurements  in  triplicate.  
  
Figure  2.9.  Impact  of  DMSO  on  A-­‐‑site-­‐‑small  molecule  binding  affinities.  Shown  are  
2-­‐‑AP  fluorescence  intensity  titration  curves  for  small  molecule  binding  to  2AP-­‐‑A92-­‐‑A-­‐‑
site  with  varying  DMSO  concentration.  A.  Paromomycin.  B.  Mitoxantrone.  Error  bars  
are  obtained  from  repeating  the  measurements  in  triplicate.  
  
All   of   the   molecules   tested   resulted   in   significant   changes   in   fluorescence  
intensity  upon  binding  to  their  RNA  targets  allowing  the  accurate  determination  of  Kds.  
In  all  cases,  the  addition  of  DMSO  slightly  weakened  the  RNA-­‐‑ligand  binding  affinity  
and  resulted  in  an  increase  in  the  measured  Kd  (Table  2.1).  This  increase  was  small  for  5%  
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DMSO  but   became   significant   at   10%  DMSO.   For   example,  while   the   addition   of   5%  
DMSO  increased  the  measured  Kd  for  ARG,  kanamycin  B,  and  mitoxantrone  by  only  1.1,  
1.2  and  1.7  fold,  respectively,  10%  DMSO  resulted  in  much  larger  increases  of  1.4,  1.5,  
and   2.8   fold,   respectively.   It   should   be   noted   that   kanamycin   B   exhibited   a   second  
weaker  and  non-­‐‑specific  binding  to  TAR  which  was  not  observable  in  the  presence  of  10%  
DMSO.  A  more  significant  1.7-­‐‑2.8  fold  increase  in  Kd  was  observed  for  the  intercalator,  
mitoxantrone  (Table  2.1).  Similar  results  and  trends  were  observed  with  A-­‐‑site,  where  
the   addition   of   5%   DMSO   increased   the   measured   Kd   for   paromomycin   and  
mitoxantrone   by   1.5   and   1.8   fold   respectively,  whereas   10%  DMSO   resulted   in  much  
larger  increases  of  2.6  and  3.9  fold  respectively  (Table  2.1).    
2AP-­‐‑U25-­‐‑TAR  
Small  Molecule   0%  DMSO   5%  DMSO   10%  DMSO  




13.7  ±0.4  nM  
10.2  ±4.1  mM  
  
16.8  ±0.4  nM  
5.5  ±1.1  mM  
  





44.1  ±1.8  nM  
  
75.4  ±4.4  nM  
  
124.5  ±4.7  nM  
2AP-­‐‑A92-­‐‑Asite  
Small  Molecule   0%  DMSO   5%  DMSO   10%  DMSO  




64.4  ±2.0  nM  
  
117.6  ±2.5  nM  
  
253.9  ±11.2  nM  
Table  2.1  Dissociation  constants   (Kds)   for  RNA-­‐‑small  molecule  binding  determined  
using  2-­‐‑AP  fluorescence  at  different  DMSO  concentrations.  
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In   general,   the   weakened   binding   affinity   observed   with   DMSO   was   not   as  
dramatic  as  that  reported  for  some  proteins(23).  However,  our  study  focused  on  hairpin  
structures;  additional  studies  are  required  with  more  complex  RNA  structures,  such  as  
riboswitches,   that   have  deeper   and   often  more   hydrophobic   binding  pockets   that   are  
more  similar  to  typical  protein  binding  sites.    
Impact  of  DMSO  on  RNA  ligand  binding  mode    
To   further   examine  whether   DMSO   affects   the   RNA-­‐‑ligand   binding   kinetics   and   the  
RNA-­‐‑ligand   bound   structure,   we   performed   NMR   chemical   shift   titrations   in   which  
spectra   of   TAR   or   A-­‐‑site   were   recorded   upon   addition   of   a   small   molecule   in   the  
presence   of   5%   DMSO   and   compared   the   NMR   titration   profiles   with   counterparts  
observed   in   the   absence   of  DMSO   (Figure   2.10).   In   both   cases,   similar   chemical   shift  
perturbations  were  observed  in  the  absence  and  presence  of  DMSO,  indicating  that  the  
exchange   kinetics   between   free   and   ligand-­‐‑bound   RNA   structure,   and   the   ligand-­‐‑
binding  mode  were  not  significantly  affected  by  DMSO.  Comparison  of   the  spectra  of  
TAR-­‐‑ARG   and   A-­‐‑site-­‐‑paromomycin   complexes   with   and   without   5%   DMSO   (Figure  
2.11)  revealed  even  smaller  differences  than  observed  for  the  unbound  RNA,  indicating  




Figure  2.10.  Examining  small  molecule  binding  to  RNA  in  DMSO  by  NMR.   Shown  
are   2D  C-­‐‑H  HSQC   spectra   of   RNA  with   small  molecules   titrated   in   the   absence   and  






Figure  2.11.  Examining  impact  of  DMSO  on  RNA-­‐‑ligand  complexes  by  NMR.  Shown  
are  2D  C-­‐‑H  HSQC  spectra  of  RNA-­‐‑small  molecules  complexes  in  absence  and  presence  
of  DMSO.  A.  TAR-­‐‑argininamide  at  1:25  molar   ratio  and  B.  A-­‐‑site-­‐‑paromomycin  at  1:3  
molar  ratio.    
  
Mechanism   of   DMSO   perturbations   and   implications   for   experimental   and   virtual  
screens  
Our   results   show   that   DMSO   promotes   the   flipping   out   of   the   flexible   non-­‐‑
canonical   residues.   This   effect   is   likely   due   to   the   increased   hydrophobicity   of   the  
solvent,  which  favors  solvation  of  the  hydrophobic  nucleobase  as  compared  to  the  polar  
water   solvent,   and  possibly  due   to  DMSO  forming  hydrogen  bonds  with  nucleobases  
and  other  hydration  effects.  Prior  studies  showed  that  organic  solvents,  including  N,N-­‐‑
dimethylformamide,   DMSO,   tetramethylurea,   methanol,   ethanol,   and   ethylene   glycol  
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denature   duplex   DNA   in   a   manner   strongly   dependent   on   their   degree   of  
hydrophobicity(30).   Another   study   has   shown   that   replacement   of   the   two   methyl  
groups   in   DMSO   with   ethyl   groups   results   in   a   more   hydrophobic   solvent  
(diethylsulfoxide  or  DESO)  that  is  more  effective  at  denaturing  duplex  DNA(31).  While  
the  DMSO  concentrations  (5%-­‐‑10%)  used  in  binding  assays  are  not  sufficient  to  disrupt  
duplex   structures,   it   can   promote   destacking   and   ‘local   melting’   of   flexible   non-­‐‑
canonical   residue,   that  are  often   the   sites  of   small  molecule  binding.  These  effects  are  
expected  to  become  even  more  pronounced  for  more  flexible  RNAs  containing  single-­‐‑
strands.   While   the   effects   of   DMSO   on   RNA   observed   here   are   smaller   than   those  
reported  for  certain  proteins(23),  they  warrant  careful  attention  before  proceeding  with  
ligand  binding  assays  and  high  throughput  screening  campaigns.    
Our   results   suggest   that   DMSO   has   a   smaller   effect   on   the   ligand   binding  
affinities  of  polycationic  aminoglycosides  that  bind  TAR  and  A-­‐‑site  primarily  through  
electrostatic   interactions,   as   compared   to   the   intercalating   mitoxantrone   that   binds  
primarily  via  hydrophobic  stacking  interactions.  One  possibility  would  be  that  DMSO  
more   strongly   perturbs   the   RNA   binding   site   for   mitoxantrone   as   compared   to   the  
aminoglycosides.  However,  comparison  of  the  chemical  shift  perturbations  induced  by  
DMSO  and   the   small  molecules  does  not  provide   any   evidence   that   the  DMSO  more  
greatly   affects   the   mitoxantrone   binding   site.   Rather,   this   effect   is   likely   due   to   the  
increase  in  the  hydrophobicity  of  the  solvent  with  DMSO,  which  favorably  solvates  the  
hydrophobic  mitoxantrone.  The  slightly  weakened  Kd  of  paromomycin   in  10%  DMSO  
could   also   be   explained   by   the   weakened   stacking   interaction   between   ring   I   of  
paromomycin  and  G91  of  A-­‐‑site(48)  due  to  increase  in  the  hydrophobicity  of  the  solvent  




Our  study  was  motivated  in  large  part  by  a  recent  virtual  screen  targeting  HIV-­‐‑1  
TAR(13).   Among   58   top-­‐‑scoring   compounds   tested,   only   14   compounds  were  water-­‐‑
soluble  and  did  not   require  DMSO  for  solubilization,  and  among  these  compounds,  7  
were   active   in   in   vitro   binding   assays.   In   stark   contrast,   among   44   water   insoluble  
compounds  that  required  DMSO  for  solubilization,  none  were  active  in  in  vitro  binding  
assays.  The  overall  hit  rate  for  the  virtual  screen  was  12%,  but  improved  to  50%  when  
excluding  compounds  that  required  DMSO  for  their  solubilization.  Our  results  suggest  
that   DMSO   is   unlikely   to   have   affected   TAR-­‐‑ligand   binding   to   such   an   extent   as   to  
completely  abrogate  binding.  Rather,  it  is  more  likely  that  the  docking  scoring  function  
used  in  the  virtual  screen  generates  false  positives  that  are  biased  toward  hydrophobic  
compounds.   Indeed,   preliminary   analysis   of   a   virtual   screen  using   a   distinct   docking  
program   and   scoring   function   reveals   a   smaller   level   enrichment   with   hydrophobic  
compounds  among  the  top  virtual  screening  hits  (data  not  shown).  
2.4 Conclusion  
We   have   investigated   how   DMSO   affects   the   structure   and   ligand   binding  
properties  of  two  well-­‐‑studied  RNA  targets,  HIV-­‐‑1  TAR  and  ribosomal  A-­‐‑site.  In  both  
cases,   typical  concentrations  (5%-­‐‑10%)  of  DMSO  used  in   ligand  binding  assays  and  in  
high   throughput   screens  destabilized  non-­‐‑canonical   residues  within  bulges   and   loops  
and   resulted   in   a   0.3–4   fold   reduction   in   the  measured  binding  affinities   for  different  
small  molecules,  with  the  greatest  reduction  observed  for  an  intercalating  hydrophobic  
compound  that  binds  RNA  non-­‐‑specifically.  Our  results  suggest  that  by  competing  for  
hydrophobic   interactions,  DMSO  can  have   some  effects  on  RNA  structure  and   ligand  
binding.   These   effects   should   be   considered  when   developing   ligand   binding   assays  
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    Chapter  3
Experimental  High  Throughput  and  Virtual  Screening  Targeting  HIV-­‐‑1  TAR  RNA  
3.1 Introduction  
   In   the   present   study,  we   screened   a   ~100,000   small  molecule   library   using   the  
fluorescence-­‐‑based   high   throughput   screening   and   the   ensemble-­‐‑based   virtual  
screening  in  order  to  identify  compounds  that  disrupts  HIV-­‐‑1  TAR-­‐‑Tat  interaction.  We  
have  identified  total  11  inhibitors  of  TAR-­‐‑Tat  interaction  from  HTS  and  VS,  one  of  them  
showing  a  promising  anti-­‐‑HIV  activity  despite  high  cytotoxicity.  We  also  showed  that  
combining  HTS  and  VS  could  enable  the  efficient  search  for  small  molecule  modulators.  
3.2 Materials  and  Methods  
Preparation  of  HIV-­‐‑1  TAR  RNA  and  Tat  peptide  
The   HIV-­‐‑1   TAR   RNA   was   prepared   by   in   vitro   transcription   using   double   stranded  
DNA  encoding  the  RNA  sequence  of  interest  and  containing  the  T7  promoter  at  5’-­‐‑end  
(Integrated  DNA  Technologies).  T7  RNA  polymerase  (Takara  Mirus  Bio,  Inc.)  was  used  
to   transcribe   the   DNA   sequence   in   the   presence   of   13C/15N   labeled   nucleotide  
triphosphates   (ISOTEC,   Inc.   and   Cambridge   Isotope   Laboratories,   Inc)   or   unlabeled  
nucleotide   triphosphates.   The   RNA   was   purified   using   20%   (w/v)   denaturing  
polyacrylamide   gel   electrophoresis   (PAGE)   in   8M   urea   and   1X   TBE.   The   RNA   was  
electroeluted  in  20mM  Tris  (pH  8)  buffer  and  then  precipitated  in  ethanol.  The  purified  
RNA   pellet   was   dissolved   and   exchanged   into   the   phosphate   buffer   (15mM   sodium  
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phosphate,   25mM   sodium   chloride,   0.1mM   EDTA,   and   pH   ~   6.4)   using   a   centricon  
ultracel  YM-­‐‑3  concentrator  (Millipore  Corp.).  For  the  fluorescence  assay,  the  RNA  was  
diluted   to   150nM   in   Tris-­‐‑HCl   buffer   (50   mM   Tris-­‐‑HCl,   50   mM   potassium   chloride,  
0.01%  (v/v)  Triton  X-­‐‑100  at  pH  ~7.4).    
   The  arginine-­‐‑rich  motif  (RKKRRQRRR)  of  Tat  is  doubly  labeled  with  fluorescein  
at   N-­‐‑terminus   and   TAMRA   at   C-­‐‑terminus.   Three   alanines   were   placed   between   the  
fluorophores  and  the  arginine-­‐‑rich  motif  to  avoid  potential  interference  on  the  binding  
affinity   against   TAR.   The   sequence   used   in   this   study   is,   N-­‐‑(5-­‐‑FAM)-­‐‑
AAARKKRRQRRRAAAK(TAMRA)-­‐‑C,  where  N  and  C  denote   the  N-­‐‑terminus  and  C-­‐‑
terminus,   respectively.   This   Tat   peptide   was   purchased   from   Lifetein   (Hillsborough,  
NJ).  The  purity  of  the  peptide  was  >  95%.    
TAR-­‐‑Tat  Displacement  Assay  
The  assay  was  first  developed  by  Matsumoto  et  al.  for  HIV-­‐‑1  TAR  (1).  The  assay  utilizes  
the   intramolecular   quenching   due   to   formation   of   dimers   between   fluorescein   and  
TAMRA   and   the   fluorescence   resonance   energy   transfer   (FRET)   effect   between  
fluorescein   and   TAMRA   (Figure   3.1).   When   the   Tat   peptide   is   in   free   solution,   the  
previous  CD   and  NMR   studies(2)   (3)   showed   that   the   peptide   does   not   form   typical  
protein  secondary  structures  (α-­‐‑helix  or  β-­‐‑sheets),  but  rather  behave  as  an  intrinsically  
disordered   protein.   The   dynamic   nature   of   the   Tat   peptide   causes   two   fluorophores  
(fluorescein   and  TAMRA)   to   form   a   dimer   each   other,   quenching   the   fluorescence   of  
both  fluorophores.  The  mechanism  of  quenching  is  called  static  quenching  that  occurs  
when  the  two  fluorophores  approach  closer  than  20  angstroms.  When  the  Tat  peptide  is  
bound  to  the  bulge  of  TAR,  the  circular  dichroism  (CD)  spectroscopy  confirmed  that  the  
peptide   transitioned   to   the   extended   conformation(4).   This   extended   conformation  
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creates   a   distance   between   the   two   fluorophores,   fluorescein   and   TAMRA,   and   the  
FRET  can  be  observed  when  the  fluorescein  is  excited  at  485  nm  and  TAMRA  emission  
at  590  nm  is  detected.  Experimentally,  the  binding  of  the  Tat  peptide  to  TAR  increases  
the  fluorescence  emission  from  TAMRA  and  the  displacement  of  Tat  peptide  by  small  
molecule  inhibitors  decreases  the  fluorescence  intensity.    
   The   dose-­‐‑dependent   curve   was   fitted   using   the   following   equation   (eq.   1)   to  
obtain  the  half  maximal  inhibitory  concentration  (IC50).  
Y =   Bottom  +   (!"#  !  !"##"$)(!!!"(!"# !"#$!!)∗!)                        (eq.  1)  
,  where  “Bottom”   is   the   lowest   signal   (due   to   inhibition),   “Top”   is   the  highest   signal,  
and   n   is   the   hill   slope.   All   variables   (Top,   Bottom,   IC50,   and   n)   are   allowed   to   float  
during  the  fitting.  Prism  (GraphPad,  Inc)  was  used  to  fit  the  dose-­‐‑response  curve  in  this  
study.  
  





Small  molecule  library  composition  and  high  throughput  screening  
The  small  molecule  library  was  obtained  from  the  Center  for  Chemical  Genomics  
(CCG)   at   University   of   Michigan   –   Ann   Arbor.   A   total   of   103,146   compounds   were  
screened.  Compounds  were  stored  as  stock  solutions  of  2  –  5  mM  compound  in  DMSO  
for  ~3  years.  The  100,000  compounds  were  synthetic  organic  molecules  with  drug-­‐‑like  
properties  purchased  from  ChemDiv  by  CCG.  Another  3,146  compounds  consistent  of  
2,000  bioactive  compounds  from  MicroSource,  446  compounds  from  National  Institute  
of  Health  (NIH)  clinical  collection,  and  700  active  compounds  against  targets  that  CCG  
screened  previously.    
   The   high   throughput   screening  was   performed   in   the   384-­‐‑well   format   (Figure  
3.2).  The  small  molecules  were  pin-­‐‑tooled  (200nL)  into  the  wells  by  Biomek  FX  384-­‐‑well  
nanoliter  HDR  (Beckman)  and  Mosquito  X1  (TTP  Labtech).  10  µL  each  of  TAR  and  Tat  
were   dispensed   to   the   entire   plate   by   using   Multidrop   reagent   dispenser   (Thermo  
Scientific).  The  final  volume  in  each  well  was  30  µL  with  50  nM  of  TAR,  20  nM  of  Tat,  
and  13  µM  of  small  molecules.  The  microplates  were  incubated  at  room  temperature  for  
10  –  15  minutes.  The  microplates  were  then  screened  using  Pherastar  plate  reader  with  
an   optical   filter   for   the   assay   (excitation:   485   nm,   emission:   590   nm).   For   each  
microplate,   the   Z-­‐‑factor(5)   was   calculated.   The   average   Z-­‐‑factor   throughout   the  HTS  




Figure  3.2.    384-­‐‑well  microplate  layout  for  HTS  
NMR  Spectroscopy  
All   NMR   experiments   were   performed   at   298K   on   600   MHz   and   800   MHz   Agilent  
spectrometers   equipped   with   5mm   triple-­‐‑resonance   cryogenic   probe.   13C/15N-­‐‑labeled  
TAR  was  exchanged  to   the  NMR  buffer   (15  mM  sodium  phosphate,  25  mM  NaCl,  0.1  
mM  EDTA  at  pH  ~6.4).  Up  to  16  µL  of  concentrated  small  molecules  was  added  to  TAR  
to  avoid  the  dilution  of  TAR  and  the  buffer  components  by  addition  of  small  molecules.  
The  aromatic  SOFAST-­‐‑HMQC  spectra  (6)  were  recorded  and  processed  using  nmrPipe  
(7)  and  SPARKY  (8).    
Cell-­‐‑based  Assays  
   The  cell  assays  were  performed  in  collaboration  with  Bieniasz  lab  at  Rockefeller  
University.   A   recombinant   HIV-­‐‑1   of   NL4-­‐‑3   and   HXB2   recombinant   strains   that   had  
green   fluorescence  protein   (GFP)   in  place  of  Nef  gene  was  used   in  all   cell  assays.  The  
virus  was  produced  by  transfecting  293T  cells  using  PEI  (6  µg  DNA  on  10cm  plate).  For  
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all   cell   assays,   any   data   points   or   spreading   infections   that   arise   from   toxicity   of   the  
small  molecules  were  excluded.  
   For   luciferase  assay  using  TZM-­‐‑bl  cell   line,  10,000  cells   /  well  were  seeded   in  a  
96-­‐‑well  plate  24  hours  before  the   infection.  Right  before   infection,   the  small  molecules  
were  diluted  in  water,  and  then  a  serial  dilution  was  done  with  media.  The  media  on  
the  TZM-­‐‑bl  cells  was  replaced  with  the  molecule-­‐‑containing  media  or  a  solvent  control.  
HIV-­‐‑1   virus  was   infected   such   that   20%  of   the   cells  were   infected.  A   luciferase   assay  
was  performed  48  hours  after  infection.  
   For   single-­‐‑cycle   infection   with   CEMx   174,   and   SUPT1   T   cell   lines,   a   similar  
protocol  to  TZM-­‐‑bl  was  used  except  that  20,000  cells  /  well  were  seeded.  After  48  hours  
from   infection,   the   cells   were   fixed   in   2%   paraformaldehyde   and   GFP+   cells   were  
detected  by  flow  cytometry  using  a  GUAVA  easycyte.    
   For  CEMx  174   spreading   infections,   200,000   cells   /  well  were   seeded   in  12-­‐‑well  
plate   with   1mL   media   with   indicated   concentration   of   compounds.   The   virus   was  
added  such  that  0.2%  of  the  cells  were  initially  infected.  24  hours  after  infection,  100  µL  
of   cells   were   taken   from   the   cultures   and   were   incubated   with   100   µg/mL   dextran  
sulfate  to  stop  further  replication.  The  cells  were  fixed  and  the  GFP+  cells  were  detected  
by  flow-­‐‑cytometry.  Every  three  days,  cells  were  split  1:3   (disposing  of  2/3  of   the  cells)  
with  fresh  media  and  compounds  added.    
Virtual  Screening  using  ICM  
The  docking  program  Internal  Coordinate  Mechanics  (ICM,  Molsoft)(9)  was  used  
for  virtual  screening.  ICM  uses  internal  coordinates  (bond  lengths,  bond  angles,  torsion  
angles,  and  phase  angles)  instead  of  conventional  XYZ  coordinates  thus  simplifying  the  
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number   of   variables   to   depict   the   positions   of   atoms   in   space,   and   reducing   the  
computation   time   to  calculate   the  small  molecule  conformation  bound   to   the   receptor  
and  the  interaction  energies.  ICM  utilizes  the  Monte  Carlo  simulated  annealing  scheme  
(10)  to  search  for  the  optimal  conformations  of  a  small  molecule  and  uses  the  following  
empirical  scoring  function  (eq.  2)  to  estimate  the  binding  affinity,  
Score = A!×E!"# + A!×N!"# + A!×E!" + A!×E!" + A!×E!"#$ + A!×E!"#$%&     (eq.  2)  
where  EVDW  is  the  van  der  Waals  interaction  energy,  NRot  is  number  of  rotatable  bonds  in  
a   ligand,   Eel  is   electrostatic   interaction   energy,   EHB   is   hydrogen   bonding   energy   term,  
Ephob   is   the   hydrophobic   energy   proportional   to   buried   surface   area   of   a   ligand  upon  
binding,   and   Edesolv   is   the   desolvation   energy   that   accounts   for   a   loss   of   hydrogen  
bonding  between  a  ligand  and  a  solvent.  The  weighting  terms,  A1  –  A6,  are  1,  0.6,  0.66,  
2.53,  0.67,  and  0.75,  respectively.    
The   choice   of   TAR   structure   and   the   ensemble-­‐‑based   docking   approach   have  
been  described  previously(11)(12).  The  same  set  of  TAR  dynamic  ensemble  comprised  
of   20   conformations   was   used   in   the   virtual   screening.   For   each   compound,   the  
minimum  score  among  the  20  conformations  was  assigned  and  used  for  analysis.    
The   same  exact   small  molecule   library  used   in   the  HTS  was  downloaded   from  
CCG.  The  protonation  and  energy-­‐‑minimization  of  small  molecules  were  completed  by  
calculator  plugins  from  JChem  packages  (ChemAxon).  The  protonation  states  of  small  
molecules  were  predicted   at  pH  5.4,   7.4,   and   9.4.   The  partial   charges   and   the   explicit  




Sphere  exclusion  clustering  is  performed  with  JKlustor  package  (ChemAxon,  Inc).  
The  clustering  begins  with  the  initial  structure  from  the  small  molecule  library.  The  next  
structure   is   randomly   chosen   and   the   chemical   similarity   between   two   molecules   is  
calculated.  If  the  similarity  is  within  the  threshold,  these  two  are  clustered  together.  If  
not,  the  second  cluster  is  generated.  The  similarity  threshold  used  in  this  study  is  80%.  
Compounds  that  are  80%  or  more  similar  are  clustered  together.    
The   chemical   similarity   is   calculated  by  Tanimoto   similarity   coefficient   (13).  The  
chemical  structures  are  converted  into  bit  strings  (a  string  of  0  and  1)   that  contain  the  
patterns   of   the   substructures   in   a  molecule.   The   following   equation   (eq.   3)   is   used   to  
calculate  the  Tanimoto  coefficient  where  N  is  the  number  of  bit  strings  in  A,  B,  or  A&B.    
Similarity  =   NA&BNA+NB−NA&B                              (eq.  3)  
3.3 Results  and  Discussion  
High  Throughput  Screening  Targeting  HIV-­‐‑1  TAR  
   The   high   throughput   screening   of   103,146   compounds   were   performed   using  
TAR-­‐‑Tat   displacement   assay(1)   in   384-­‐‑format   (Figure   3.3).   The   2812   compounds   that  
showed   activity   above   three   standard   deviations   of   the   negative   controls   were  
measured  in  triplicate  to  confirm  their  activity.  Out  of  2812  compounds,  267  compounds  
were  confirmed  to  be  active  and  the  dose  response  curves  with  the  concentration  range  
from   1  µM   to   100  µM  were  measured.   In   addition,   the   fluorescence   intensities   in   the  
presence   of   Tat   and   the   confirmed   compounds   only   were   recorded   in   order   to  
discriminate  the  compounds  that  interfere  with  the  fluorescence  signals  from  Tat.    
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The  majority  of  the  confirmed  hits  (>75%)  interfered  with  the  fluorescence  signals  of  Tat  
and  they  were  excluded  from  further  analysis.  Finally,  22  hits  were  confirmed  by  dose  
response   curves   with   pIC50   between   4   and   5.   These   22   hits   were   purchased   as   fresh  
powder   and   re-­‐‑tested   for  
reproducibility.   Unfortunately,   5   hits  
were   no   longer   available   from   the  
commercial  sources  and  excluded  from  
analysis.  The  retesting  of  the  remaining  
17   hits   yielded   9   compounds   of  which  
their   activities   were   reproducible  
(Figure   3.4).   The   8   compounds   that  
failed   to   reproduce   the   inhibitory  
activity  of  TAR-­‐‑Tat  interaction  could  be  
due   to   the   contaminations   of   the   CCG  
stock   compounds.   These   compounds  
could  also  react  with  DMSO  over  a  long  period  of  time.    
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Figure  3.4  IC50  of  9  hits  from  HTS.  The  IC50s  were  measured  in  the  absence  (blue)  and  
the  presence  of  excess  tRNA  (red)  
  
The  dose  response  curves  of  the  9  compounds  were  measured  in  the  absence  and  
the  presence  of  100-­‐‑fold  excess  tRNA  (Baker’s  Yeast)  in  order  to  test  for  the  specificity  of  
the   inhibitory   activities   (Figure   3.4).   First,   the   average   log   IC50   of   all   9   hits   is   low  
micromolar  range  (~31  µM).  Strikingly,  all  of  the  9  hits  showed  high  specificity  to  TAR  
against   the   excessive   tRNA   (3-­‐‑fold   and   100-­‐‑fold   excess),  whereas   a   neomycin   control  
which  is  known  to  bind  both  TAR  and  tRNA  strongly,  showed  deteriorated  IC50  by  an  
order  of  magnitude,  from  log  IC50  of  3.36  in  the  absence  of  tRNA  to  4.88  in  the  presence  
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Figure  3.5  NMR  titration  spectra  of  9  hits  from  HTS.  Shown  are  the  aromatic  SOFAST-­‐‑
HMQC  spectra  of  wtTAR  in  presence  of  each  9  hits.    
     
Next,   we   subjected   the   9   hits   to   NMR   spectroscopy   to   further   validate   their  
binding  to  TAR.  We  measured  the  SOFAST-­‐‑HMQC(6)  on  aromatic  carbons  to  probe  the  
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structural   change   of   TAR   upon   binding   of   compounds   (Figure   3.5).   The   compounds    
(208662,   208677,   133868,   133879,   and   133895)   exhibited   strong   chemical   shift  
perturbations   of   TAR   resonances,   showing   that   the   compounds   bind   to   TAR   tightly.  
Unfortunately,   the   other   4   compounds   (106134,   111926,   160257,   and   199937)   did   not  
induce   the   chemical   shift   perturbations   of   TAR   resonances   due   to   compound  
precipitating  in  the  NMR  tube.  The  precipitations  were  due  to  low  concentration  (<  1%  
by  volume)  of  DMSO  in  the  tube.  Increasing  the  concentration  of  compound  106134  to  
achieve  32:1  compound-­‐‑TAR  molar  ratio,  thereby  increasing  the  DMSO  concentration  to  
3%   (v/v),   seemed   to   partially   solubilize   the   compound   106134,   as   new   resonances  
appeared   in   the   NMR   spectrum   possibly   from   the   free   and   solubilized   compound  
106134.  Yet,  there  were  no  significant  chemical  shift  perturbations  on  TAR  resonances.  
This   might   imply   that   the   poor   solvation   of   compound   106134   might   have   affected  
binding  to  TAR.  
   During  the  dose-­‐‑response  curve  measurements  using  the  fluorescence  assay,  the  
compounds  133868,  133879,  133895  showed  changes  in  color  over  time  when  exposed  to  
light.  The  color  changed  from  orange  to  blue  over  the  course  of  an  hour  in  the  presence  
of  light.  When  the  compounds  were  orange,  the  fluorescence  assay  could  not  determine  
the   dose-­‐‑response   curves   due   to   fluorescence   interference   from   the   compounds  with  
fluorescein   and   TAMRA.   However,   when   the   compounds   changed   to   blue,   the  
fluorescence  assays  yielded  the  dose-­‐‑response  curves  (Figure  3.4).  The  NMR  spectra  of  
these  compounds  bound  to  TAR  showed  that  the  chemical  shift  perturbations  were  the  
same  regardless  of   the  color  change.  This  showed  that   the  compound  binding  to  TAR  
was  not  affected  by  the  color  change.    
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The   compounds   133868,   133879,   133895   are   anthraquinone   binders.   A   possible  
mechanism  of  their  color  change  has  been  proposed  in  a  previous  study(14)  (Figure  3.6).  
In  that  mechanism,  DMSO  reacts  with  the  anthraquinone  
to   form  DMSO-­‐‑anthraquinone.  This  complex  exhibits  an  
orange   color,   consistent   with   our   observation   of   the  
compounds   in   100%   DMSO.   When   this   DMSO-­‐‑
anthraquinone  is  exposed  to  water,  the  DMSO  dissociates  
and   the   color   of   the   anthraquinone   becomes   blue,  
consistent   with   what   we   have   observed   in   the  
fluorescence  and  the  NMR  experiments.  It  is  still  unclear,  
however,  how  an  exposure  to  light  catalyzed  the  color  changing  reactions  with  DMSO.    
  
Figure   3.6   Reaction   of  




Figure  3.7  Cell  Assays  of  HTS  hits.  A.  Single-­‐‑cycle  infections  on  T-­‐‑cell  lines  B.  Single-­‐‑
cycle   infections   in   TZM-­‐‑bl   cells.   Sisomicin   and   netilmicin   were   controls.   C.   HIV-­‐‑1  
spreading  infections  in  CEM  x174  (T-­‐‑cell).  
  
Next,   the   anti-­‐‑HIV   activities   of   the   9   hits   were   evaluated   with   single-­‐‑cycle  
infections  with  T-­‐‑cell  lines  (CEM  x174  and  SUPT1),  and  a  reporter  cell  line  (TZM-­‐‑bl),  in  
collaboration   with   the   Bieniasz   lab   at   Rockfeller   University   (Figure   3.7A   and   Figure  
3.7B,   respectively).   The  HIV-­‐‑1   strain   in  T-­‐‑cell   lines   is   recombinant   strain  with  GFP   in  
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production   is   monitored   by   the   GFP   fluorescence.   The   TZM-­‐‑bl   has   HIV-­‐‑1   LTR   with  
luciferase  gene.  The  effect  of  small  molecules  in  viral  transcription  is  monitored  by  the  
luminescence  from  the  luciferase.  Out  of  9  compounds,  one  compound  106134,  showed  
promising   anti-­‐‑HIV   activity.   In   T-­‐‑cell   lines,   the   compound   106134   showed   20   –   30%  
changes  in  GFP  fluorescence  signal  at  2.5  µM  concentrations  in  CEM  x174  cells  and  at  
500  nM  concentrations  in  SUPT1  cells  (Figure  3.7A).  In  TZM-­‐‑bl  cell  line,  the  compound  
106134  showed  70%-­‐‑80%  decrease  in  luciferase  signal  at  2.5  µM  concentrations  (Figure  
3.7B).  The  compound  111926  was  weaker,  showing  23%  decrease  in  luciferase  signal  at  
500   nM   concentrations   in   the   first   trial,   but   the   activity   was   not   reproducible   in   the  
second  trial.  It  is  possible  that  the  compound  111926  is  inactive  or  very  weak  inhibitor.  
Interestingly,   the   compound   111926   showed   a   small   inhibitory   activity   in   HIV-­‐‑1  
replication   over   a   week   (Figure   3.7C),   even   though   it   was   inactive   or   very   weak  
inhibitor  in  the  single-­‐‑cycle  infection  experiments.  It  might  suggest  that  the  compound  
111926  has  off-­‐‑targets  that  inhibit  the  HIV-­‐‑1  replication.    
  
Virtual  Screening  Targeting  HIV-­‐‑1  TAR    
   The   same  small  molecule   library  as   the  HTS   (103,146   compounds)  was  used   to  
screen   small   molecules   against   the   dynamic   ensemble   of   20   TAR   conformers(12).   In  
order  to  compare  the  docking  with  the  HTS  without  a  bias,  the  workflow  of  the  virtual  
screening  (VS)  was  similar  to  the  HTS  (Figure  3.8).  After  the  primary  screening,  the  top  
2812  compounds  were  subjected  to  the  confirmation  stage  where  they  were  docked  in  
triplicates.  The  top  267  compounds  that  showed  docking  scores  with  standard  deviation  
less  than  3  were  subject  to  the  rigorous  docking  by  increasing  the  sampling  time.  This  
rigorous   docking   is   equivalent   to   the   dose-­‐‑response   curve  measurement   in  HTS.   The  
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top  17  commercially  available  compounds  were  purchased  and  tested  with  the  TAR-­‐‑Tat  
displacement  assay.    
  
Figure  3.8  Comparison  of  screening  workflow  between  HTS  and  VS  
     
Among  the  17  final  hits  from  VS,  two  compounds,  rhapontin  and  capreomycin,  
showed  activity  with  IC50  of  178  µM  and  31  µM,  respectively  (Figure  3.9).  The  hit  rate  
of   the   virtual   screening   was   ~12%,   which   was   comparable   to   the   previous   virtual  
screening  (12).  This  results  in  the  enrichment  rate  of  >1300  by  VS  when  only  accounting  
for   experimentally   tested   compounds.      The   predicted   bound   pose   of   the   rhapontin  
showed   that   it   would   bind   to   the   apical   loop   of   TAR,   while   the   bound   pose   of   the  
capreomycin   predicted   that   it   would   interact   with   both   bulge   and   the   apical   loop  
(Figure   3.10).   Indeed,   NMR   titration   of   capreomycin   in   6:1   molar   ratio   with   TAR  
resulted  in  significant  chemical  shift  perturbations  around  the  bulge,  suggesting  that  it  
may  bind  to  the  bulge.  The  binding  of  rhapontin  in  6:1  molar  ratio  did  not  perturb  the  
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chemical   shifts   of   TAR,   possibly   due   to   weak   binding   affinity.   Unfortunately,  
capreomycin  and  rhapontin  did  not  show  activities  in  cells  (Figure  3.7B).    
  
Figure  3.9  Dose-­‐‑response  curves  of  hits  from  virtual  screening  
  
Figure  3.10  NMR  chemical  shift  perturbations  and  ICM  predicted  bound  pose  of  hits  
from  virtual  screening  
  
log IC50 = 4.49 ±0.03 nM
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Comparison  of  Virtual  Screening  and  High  Throughput  Screening    
   The   structures  of   the   small  molecule  hits   from  HTS  and   the  hits   from  VS  were  
very   different.   None   of   the   9   hits   from   the  HTS  were   selected   as   hits   by   the   virtual  
screening,   and   likewise   capreomycin   and   rhapontin  were   not   selected   as   hits   by   the  
HTS.   It   is   possible   that   HTS   did   not   select   capreomycin   in   the   screening,   because  
capreomycin  was  not  soluble  in  DMSO.  However,  the  ICM  should  have  selected  the  9  
hits   from   the  HTS.   Looking   at   the   histogram   of   ICM   scores   of   the   entire   compound  
library  (Figure  3.11),   the  9  hits  were  all  scored  near  the  mean  of  the  score  distribution  
(ICM  score  ~   -­‐‑21  kcal/mol).  The  best-­‐‑scored  compound  was   ranked  at  2,089th,   and   the  
least   scored   compound   was   ranked   at   89,440th.   Interestingly,   the   compound   106134,  
which  showed  anti-­‐‑HIV  activity  in  cells,  were  ranked  89,440th.    
It  is  questionable  whether  the  ICM  scoring  function  was  indeed  the  problem  for  
the  false  negatives.  In  order  to  address  this  question,  we  have  selected  two  best-­‐‑scored  
compounds   from   the   dose-­‐‑response   measurements   in   HTS.   These   compounds   were  
tested   by   NMR   due   to   fluorescence   interference   (Figure   3.12).   The   first   compound  
135485,  which  was  ranked  14th  by   ICM,  was  not  available  commercially  and  excluded  
from   analysis.   The   second   compound,  Rutin,  was   ranked   33rd   by   ICM,   but   it   did   not  
show   binding   to   TAR   at   6:1   molar   ratio   by   NMR.   The   third   compound,   compound  
133905,  was  ranked  639th  by  ICM,  and  it  did  bind  to  TAR  strongly  at  6:1  molar  ratio  by  
NMR.  Looking  at   the  molecular  structure  of   the  compound  133905,   it  shares  the  same  
scaffold  with   the   compound  133868,   133879,   and   133895,  which  were   ranked   55,369th,  
7,008th,   and   5,485th   by   ICM,   respectively.   These   results   suggested   that   the   poor  
enrichment   of   active   compounds   by   ICM   could   be   due   to  many   high-­‐‑scored   inactive  
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Figure  3.12  NMR  titrations  of  compound  133905  and  Rutin  
  
Given   the   broad   distribution   of   compounds   that   have   similar   scaffolds,   we  
hypothesized  that  by  clustering  the  compounds  by  chemical  similarity,  the  enrichment  
rate  of   ICM  would   increase,  because  putatively   inactive  compounds  will  be  clustered,  
reducing   the   number   of   inactive   compounds   ranked   among   the   actives.   Here,   we  
assume  that  the  chemically  similar  compounds  also  share  the  similar  activity.  Using  the  
sphere   exclusion   clustering,   we   clustered   the   entire   small   molecule   library   with  
chemical   similarity   threshold  80%  or  more   (Figure  3.13).  This  means   that   each   cluster  
will   contain   80%   or   more   similar   compounds   to   each   other.   The   80%   threshold   was  
chosen   to   optimize   the   similarity   within   each   cluster.   The   entire   library   of   103,146  
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compounds  was  reduced  to  25,446  representative  clusters  (4-­‐‑fold  decrease).  There  are  7  
representative   clusters   for   the   hits   from   HTS,   because   the   chemical   structures   of  
compound  133895,  133879,  and  133868  were  clustered.    
  
Figure  3.13   ICM  score  histogram  of   the   reduced  chemical   library  by  clustering.   The  
numbers  above  the  molecule  show  the  number  of  similar  compounds  in  a  cluster  and  
the  ICM  score  ranking  of  a  cluster.  
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The   histogram   of   best   ICM   score   from   each   cluster   was   compared   with   the  
original   ICM   score   distribution.   The   clustering   improved   the  mean   ICM   score   of   the  
histograms  marginally  from  ICM  score  of   -­‐‑21  kcal/mol  to  -­‐‑22  kcal/mol,  but  there  were  
notable  changes  in  distributions  of  active  compounds  from  HTS.  For  example,  the  ICM  
score   of   compound   106134   improved   from   -­‐‑16   kcal/mol   to   -­‐‑22   kcal/mol   and   the   ICM  
score   of   the   compound   133868   improved   from   -­‐‑20   kcal/mol   to   -­‐‑39   kcal/mol.   The  
improvements   on   ICM   scores   were   more  
significant  for  a  cluster  of  similar  compounds  that  
had   wide   range   of   ICM   scores   as   shown   in   the  
case   of   anthraquinones   (compound   133895,  
133879,   and   133868).   The   enrichment   rate  
calculated  by  the  receiver  operating  characteristic  
curve   (ROC)(15)   shows   that   the   clustering  
improved   the   enrichment   by   ~20%   based   on   the  
areas  under  the  curves  (Figure  3.14).    
3.4 Conclusion  
In   the  present   study,  we  have   identified   11   small  molecule   (IC50   ~   30   –   170µM)  
inhibitors   of   TAR-­‐‑Tat   interaction   from  HTS   and   VS.   One   of   the   compounds   showed  
small  but  promising  anti-­‐‑HIV  activity  despite  high  cytotoxicity.  The  hits  from  HTS  and  
VS  did  not  overlap  at  all,   suggesting   that   the  HTS  and  VS  are  complimentary   to  each  
other.  While  the  VS  is  more  efficient  with  enrichment  rate  larger  than  1300  compared  to  
HTS,  ICM  poorly  enriched  the  hits  from  HTS.  Clustering  the  chemical  library  improved  
the   enrichment   rate   by   ICM,   suggesting   that   there   are  many   false   positives   (inactive  
compounds  that  are  highly  scored)  that  share  the  similar  chemical  scaffolds.  Clustering  
Figure   3.14   Improvement   on   ICM  
enrichment  rate  by  clustering.  























Number of Discarded Compounds (1-Sp)
 Clustered Library (AUC = 0.86)
 Original (AUC = 0.72)
 Random (AUC = 0.5)
 Ideal (AUC = 1.0)
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can  also  reduce  the  number  of  small  molecules  that  the  HTS  needs  to  screen.  Therefore,  
combining  HTS  and  VS  will  boost  the  efficiency  of  the  drug  discovery.    
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    Chapter  4
A  Sparsely  Populated  Transient  State  Gives  Rise  to  Long-­‐‑Range  Correlated  Changes  
in  RNA  Secondary  Structure  
4.1 Introduction  
Many   ribonucleic   acids   (RNA)   do   not   fold   into   a   single   static   conformation   but  
rather   can   populate   a   wide   range   of   conformation   along   a   rugged   free   energy  
landscape(1,  2).  Cellular  cues  ranging  from  changes  in  physiochemical  parameters  such  
as  temperature  and  pH  to  the  binding  of  proteins,  RNAs,  and  ligands  have  been  shown  
to   preferentially   stabilize   different   RNA   conformations   along   this   free   energy  
landscape,   resulting   in   dynamic   change   in   structure   that   play   crucial   roles   in   the  
catalytic  activity  of  ribozymes(3),  regulatory  activity  of  riboswitches(4)  and  other  RNA-­‐‑
based   switches(5-­‐‑8),   and   in   the   hierarchical   assembly   and   disassembly   of   ribonucleic  
acid-­‐‑  protein  complexes(9-­‐‑11).    
One  of  the  most  ubiquitous  and  fundamental  mode  of  RNA  functional  dynamics  
involves  large-­‐‑scale  changes  in  secondary  structure,  typically  triggered  by  external  co-­‐‑
factors(12)  or  with  the  aid  of  ATP-­‐‑dependent  chaperones(13,  14),  sometimes  during  co-­‐‑
transcriptional  folding(7,  15),  that  serve  to  expose  or  sequester  key  regulatory  elements.    
Recently,   NMR   R1ρ   relaxation   dispersion   experiments(16-­‐‑19)   in   concert   with  
mutagenesis(20)   have   helped   uncover   a   new   mode   of   RNA   secondary   structure  
dynamics   involving  much  more  rapid  and  localized  transitions   in  secondary  structure  
representing   excursions   away   from   the   energetically   favorable   ground   state   (GS)  
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towards   low   populated   (typically   populations   <15   %)   and   short-­‐‑lived   (lifetime   <  
milliseconds)  species  often  referred  to  as  excited  states   (ES).     These   transitions   feature  
subtle   changes   in   base-­‐‑pairing   in   and   around   non-­‐‑canonical   motifs   such   as   bulges,  
internal  loops,  and  apical  loops(20).  As  for  larger-­‐‑scale  secondary  structural  transition,  
transitions   towards  RNA  ESs   can   sequester   functionally   important   residues   via   base-­‐‑
pairing  that  otherwise  have  to  be  available   in  order   to   interact  with  cellular   factors  or  
promote  ATP-­‐‑independent   large-­‐‑scale  changes   in  secondary  structure(18,  19).  Because  
these  localized  changes  in  secondary  structure  occur  at  rates  that  are  two  to  four  orders  
of  magnitude   faster   than  conventional  RNA  secondary  structural   transitions,   they  can  
potentially  meet  unique  demands  in  RNA-­‐‑based  regulatory  functions  (20).    
Using   NMR   R1ρ   relaxation   dispersion   experiment(21-­‐‑23),   we   recently  
reported(20)  an  excited  state  for  the  apical  loop  of  the  transactivation  response  element  
(TAR)   from   the   human   immunodeficiency   virus   type-­‐‑1   (HIV-­‐‑1)   RNA(24)   that   has   a  
population   of   ~13%   and   exceptionally   short   lifetime   of   ~45   microsecond.   TAR   is   a  
regulatory   viral   RNA   located   at   the   5ʹ′-­‐‑end   of   the   HIV   retroviral   genome   that   plays  
many   roles   in   HIV   viral   replication,   including   transcription   elongation(25-­‐‑28),   viral  
translation(29,   30),   dimerization(31,   32),   packaging(32,   33),   and   viral   latency(34,   35).  
TAR  contains  two  motifs  that  play  essential  roles  in  protein  recognition;  a  trinucleotide  
bulge  and  a  hexanucleotide  apical  loop  that  are  separated  by  a  four  base-­‐‑pair  helix(36).    
The  TAR  bulge  and  apical  loop  also  serve  as  binding  sites  for  small  molecules  that  are  
being   developed   as   anti-­‐‑HIV   therapeutics(37-­‐‑40).   In   the   ground   state,   the   apical   loop  
forms   a   conformation   that   exposes   residues  C30,  U31,  G32,   and  A35   so   that   they   are  
exposed  and  available   to   interact  with  binding  partners(36,   41-­‐‑43).  The  ES   (which  we  
will  refer  to  as  ES1)  features  a  more  compact  apical   loop  structure  in  which  C30,  U31,  
G34,   and  A35   are   sequestered   through   formation   of  A+-­‐‑C   and  U31-­‐‑G34   trans-­‐‑wobble  
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base-­‐‑pairs(20).   Importantly,   mutations   that   stabilize   the   ES1(20)   are   correlated   to   the  
reduced  binding  affinity  to  Tat/cyclin  T1  proteins  as  well  as  the  reduced  efficiencies  of  
transcriptional  activation(44),  implying  a  potential  regulatory  role.  
During   our   studies,   we   also   obtained   evidence   for   a   slower   process   directed  
toward  a  second  distinct  excited  state  (which  we  refer  to  as  ES2)  involving  apical  loop  
residues  G33  and  A35.  This  ES  has  a  much  lower  population  (pB)  of  ~0.4%  and  longer  
lifetime  (τ)  of  ~2  milliseconds.  It  is  remarkable  that  A35  simultaneously  senses  the  two  
ESs;  with   the   sugar  C1ʹ′   sensing   the   fast  process   toward  ES1   and  base  C8   sensing   the  
slower   process   toward   ES2.   Here,   we   perform   a   broader   set   of   NMR   relaxation  
dispersion  experiments  aimed  at  characterizing  the  second  transient  state  (ES2)  in  HIV-­‐‑
1   TAR.   Our   results   reveal   a   rearrangement   in   secondary   structure   that   results   in  
correlated   changes   in   secondary   structure   from   the   tip   of   the   apical   loop   toward   the  
lower   stem   of   HIV-­‐‑1   TAR.   This   ES   can   possibly   explain   functional   data   hinting   at  
allosteric  communication  between  the  TAR  bulge  and  apical  loop.  These  results  provide  
fundamental  new  insights  into  transient  structure  landscape  of  RNA  and  suggest  a  new  
mechanism  for  RNA  based  allostery  involving  transient  states.    
4.2 Materials  and  Methods  
Preparation  and  NMR  resonance  assignment  of  labeled  and  unlabeled  RNA    
RNA  samples  (wt  TAR,  TAR-­‐‑UUCG,  TAR-­‐‑G28U,  and  TAR-­‐‑Δbulge)  were  prepared  by  in  
vitro   transcription   using   T7   RNA   polymerase   (Takara   Mirus   Bio,   Inc.),   uniformly  
13C/15N-­‐‑labeled   nucleotide   triphosphates   (ISOTEC,   Inc.,   Cambridge   Isotope   Labs)   and  
synthetic   DNA   templates   (Integrated   DNA   Technologies,   Inc.)   containing   the   T7  
promoter  and  sequence  of   interest.  All  RNAs  were  purified  by  20  %  (w/v)  denaturing  
polyacrylamide  gel  electrophoresis,  using  8M  urea  and  1x  TBE.  The  RNA  was  electro-­‐‑
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eluted  from  the  gel  in  20  mM  Tris  buffer  at  pH  8  followed  by  ethanol  precipitation.  The  
RNA  pellet  was   dissolved   in  water,   annealed   by   heating   to   95   °C   for   5  minutes   and  
rapid   cooling  on   ice   and   exchanged   into  NMR  buffer   (15  mM  sodium  phosphate,   0.1  
mM  EDTA,  and  25  mM  NaCl  at  pH  6.4)  by  multiple   times  using  a  Centricon  Ultracel  
YM-­‐‑3   concentrator   (Millipore   Corp.).   Unlabeled   RNA   samples   (TAR-­‐‑G28U)   were  
purchased   from   Dharmacon   (Thermo   Fisher   Scientific)   and   dissolved   in   water   for  
annealing   as   described   above   and   exchanged   into   NMR   buffer   (15   mM   sodium  
phosphate,   0.1  mM  EDTA,   25  mM  NaCl   at   pH   6.4).   For  NMR   experiments   in   ~100%  
D2O,   the   sample   in   the   NMR   buffer   was   lyophilized   for   24   hours   first,   followed   by  
adding  99.99%  D2O  (Cambridge  Isotope  Labs)  and  lyophilized  again  for  24  hours.  The  
lyophilized  pellet  was  finally  dissolved  in  the  same  volume  of  D2O  as  the  NMR  buffer.  
For  the  argininamide  (ARG)  studies,  1  µL  of  the  concentrated  ARG  solution  in  the  NMR  
buffer   at   pH   6.4  was   added   to   the  wt   TAR   to   achieve   final   16:1  ARG:wt   TAR  molar  
ratio.    
All  NMR  assignment  experiments  were  performed  on  Bruker  Avance  600  MHz  
NMR  spectrometer  or  Agilent  600  MHz  NMR  spectrometer,  both  of  which  are  equipped  
with  a  5  mm  triple-­‐‑resonance  cryogenic  probe.  The  NMR  assignments  of  wt  TAR,  TAR-­‐‑
UUCG,   TAR-­‐‑Δbulge   were   published   previously.   The   resonances   of   TAR-­‐‑G28U   were  
assigned   using   2D  HCCNH-­‐‑TOCSY(45)   that   correlates   imino   protons   of   G   and   U   to  
their  C8  and  C6,  respectively,  2D  HCN(46),  2D  15N-­‐‑edited  NOESY  (150ms  mixing  time),  
and   2D   NOESY   experiments(47)   (200ms   and   300ms   mixing   times).   The   NOESY  
experiments  were  also  performed  with  TAR-­‐‑G28U  in  ~100%  D2O.  Except  for  15N-­‐‑edited  
NOESY  which  was  performed  at  10.5oC,  all  experiments  were  performed  at  25oC.  
Carbon  and  nitrogen  R1ρ  relaxation  dispersion    
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All  NMR   relaxation  dispersion   experiments  were  performed  on   a  Bruker  Avance   600  
MHz   NMR   spectrometer   equipped   with   a   5   mm   triple-­‐‑resonance   cryogenic   probe.  
Experiments  were  performed   at   25°C,   and   35°C  using  uniformly   13C/15N   labeled  TAR  
samples.   Rotating   frame   carbon(21)   and   nitrogen(48)   R1ρ   relaxation   dispersion   data  
was  measured  using   a   1D  acquisition   scheme   that   extends   the   sensitivity   to   chemical  
exchange   into  millisecond  timescales  relative  to  conventional  2D  relaxation  dispersion  
methods.   On-­‐‑   and   off-­‐‑resonance   relaxation   dispersion   data   was   recorded   at   various  
spinlock  and  at  various  offset   frequencies  and  spinlock  powers,   respectively,   listed   in  
Table  S1.  For  each  nucleus,  the  maximum  relaxation  delay  was  determined  by  the  signal  
intensity  being  30%  of  the  initial  signal  without  the  delay.  When  our  technical  limit  of  
the   relaxation   delays   for   carbon   (55ms)   and   nitrogen   (80ms)   were   reached   without  
reducing   the   signal   intensity   to   30%,   these   limits   became   the   maximum   relaxation  
delays  regardless  of  the  signal  intensity.  Between  the  0  ms  and  the  maximum  relaxation  
delay,   6-­‐‑10   relaxation   delays   were   used   to   characterize   the   mono-­‐‑exponential   decay  
curve.  Two  duplicate  delays  were  also  included  for  error  analysis.  Data  were  processed  
using   nmrPipe(49)   and   the   R1ρ   values   were   computed   by   fitting   the   resonance  
intensities   with  mono-­‐‑exponential   decays   using  Mathematica   6.0   script(50)   (Wolfram  
Research,   Inc.,   Champaign,   IL).   Errors   in   R1ρ   were   determined   using   the   standard  
Monte  Carlo  simulations  with  500  iterations.  Measured  on-­‐‑  and  off-­‐‑resonance  relaxation  
dispersion   data   was   fitted   to   the   two-­‐‑state   Laguerre(51)   equation   in   Origin   8.5.1  
(OriginLab).  
Laguerre:  
  (Eq.  1)  
R1! = R1 cos2" + R2 sin2" +
sin2" pGS pES!# 2kex
#GS
2 #ES
2 /#eff2 + kex2 " sin2" pGS pES!# 2 1+ 2kex













,   ,   ,  
where   R1   and   R2   are   the   intrinsic   longitudinal   and   transverse   relaxation   rates,  
respectively,  (assumed  to  be  identical  for  GS  and  ES  species),  Ω  is  the  resonance  offset  
from  the  spinlock  carrier,  ωeff   is  the  spinlock  strength;  Ω  =  tan(ωeff/Ωave),  Δω  =  ΩES  -­‐‑  ΩGS,  
Ωobs  =  pGSΩGS  –  pESΩES,  where  pGS  (pES)   is   the  ground  (excited)  state   fractional  population  
(pGS  +  pES  =  1);  kex  =  k1  +  k-­‐‑1  is  the  exchange  rate  constant  for  a  two-­‐‑state  equilibrium,  where  
k1  =  pES*kex  and  k-­‐‑1  =  pGS*kex  are  the  forward  and  reverse  rate  constants,  respectively.  Note  
that  for  pES  <1%,  Ωobs  ~  ΩGS.  
Model   selection   was   carried   out   using   F-­‐‑test,   which   uses   chi-­‐‑square   (χ2   –  
applying   the   Levenberg   –Marquardt   minimization   algorithm)   to   determine   the  
feasibility  of  a  model  (e.g.  2-­‐‑state  Laguerre  equation)  versus  a  more  complex  model  (i.e.  
3-­‐‑state  equation)  expanded  from  the  first  model.    
Note   that   G28-­‐‑C8   also   showed   a   sign   of   relaxation   dispersion,   but   it   was  
excluded   from   our   analysis   because   we   were   not   able   to   retrieve   the   pB   and   the  
exchange   rate   constant   (kex)   reasonably   from   fitting   with   the   two-­‐‑state   Laguerre  
equation  (Figure  4.1).  
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Figure  4.1  R1ρ   relaxation  dispersion  profiles  of  G28-­‐‑C8  in  wt  TAR  
Thermodynamic  analysis    
The  free  energy  difference  between  the  GS  and  ES  was  calculated  by  the  modified  van’t  
Hoff  equation.(52)    
ln !! !! = ln !!!! − !!i! !hm!!hm − !!i!! !! − !!hm                                                                                                                               (Eq.  2)  
where   ki   (i   =   1,   -­‐‑1)   is   the   forward   and   backward   rate   constant   of   the   two-­‐‑state  
equilibrium,   ∆Gi!   and   ∆Hi!   are   the   free   energy   and   the   enthalpy   of   activation,  
respectively.  R  and  T  are  the  gas  constant  and  the  temperature  in  Kelvin,  respectively.  
kB   and   h   are   Boltzmann’s   constant   and   Planck’s   constant,   respectively.   κ   is   the  
transmission   coefficient   which   is   assumed   to   be   1   in   the   pre-­‐‑exponential   factor   of  
Eyring’s  theory.  Thm  is  the  harmonic  mean  of  the  experimental  temperatures  calculated  
by  Thm = n/ ( !!!)!!!!   .  
MC-­‐‑fold  predictions  of  RNA  secondary  structure    






































R1 = 1.91 ±0.02 Hz
R2 = 30.90 ±0.05 Hz
pB = 0.65 ±0.85 %
Δω = 1.6 ±0.1 ppm
kex = 252 ±359 Hz
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All   RNA   secondary   structures   except   the   full-­‐‑length   TAR   sequences   were   predicted  
based  on   sequence  using   the  program  MC-­‐‑Fold(53)  with   standard   input   options.  The  
full-­‐‑length  TAR   sequences  were  predicted  using   the   same  program  but  with   the   best  
500  structures  among  the  30%  sub-­‐‑optimal  structures.    
H-­‐‑Factor  analysis  of  NMR  chemical  shifts    
The   H-­‐‑factor   (manuscript   in   preparation)   analysis   was   performed   with   13C   chemical  
shifts  of  wt  TAR  and  the  chemical  shifts  from  the  relaxation  dispersion  (Δω),  using  the  
in-­‐‑house  program.  
4.3 Results  and  Discussion  
Observation  of  chemical  exchange  involving  the  HIV-­‐‑1  TAR  bulge  and  apical  loop.    
We   previously   showed   that   G33-­‐‑C8,   G33-­‐‑C1ʹ′   and  
A35-­‐‑C8   experience   slow   chemical   exchange   towards  
an  excited  state  (ES2,  pB  =  ~0.4%  and  τ  =  ~2ms)  that  is  
distinct  from  the  ES1  (pB  =  ~13%  and  τ  =  ~45µs),  which  
is   sensed   by   virtually   all   other   apical   loop  
residues(20)   (Figure   4.2).   To   obtain   further   insights  
into  ES2,  we  performed  a  broader   set   of   carbon  and  
nitrogen  NMR  R1ρ  relaxation  dispersion  experiments  
targeting   residues   throughput   HIV-­‐‑1   TAR.  
Unexpectedly,  we   found   evidence   for   slow   chemical  
exchange   in   several   TAR   resonances   located   in   the  
upper   stem   (A27-­‐‑C1ʹ′   and   U38-­‐‑N3),   bulge   (U23-­‐‑C6  





















G21 C8, C1′, N1
G26 C8
A22 C8, C2, C1′
















A35 C8, C1′C30 C1′
U31 C1′ G34 C8, C1′
Figure   4.2   Secondary   structure  
of   HIV-­‐‑1   TAR.   Sites   showing  
slow,   fast,   and   no   chemical  
exchange   are   highlighted   in  




Several  residues  showed  no  evidence  for  chemical  exchange,  including  A20,  G21,  U42,  
and  G43  in  the  lower  stem  and  G26,  C29,  G36,  C37,  and  C39  in  upper  stem  (Figure  4.3).  
The  two-­‐‑state  analysis  ( )  of  these  newly  measured  R1ρ  relaxation  dispersion  
data  (Figure  4.4)  using  the  Laguerre  equation(51)  revealed  an  exchange  process  directed  
to  distinct  ES  that  has  a  smaller  population  (pB  ~  0.26-­‐‑0.66%)  and  longer  lifetime  (τ =  1.2  –  
3.1  ms)   and   that   is   very   similar   to   that   observed   for   the   slow  exchanging   apical   loop  
residues  (G33-­‐‑C1ʹ′,  G33-­‐‑C8,  and  A35-­‐‑C8)  where  pB  =  ~0.4  %  and  τ  =  ~2  ms.  Indeed,  based  
on  the  global  fit  (Table  4.1),  the  R1ρ  data  collected  for  all  of  the  above  residues  could  be  
combined  into  a  single  two-­‐‑state  fit  with  pB=0.40  ±0.05  %,  lifetime  of  τ  =  2.1  ±0.3  ms.    




Figure  4.3  R1ρ   relaxation  dispersion  profiles  of  wt  TAR  that  showed  no  dispersion  at  
25  oC.  The  plot  with  the  asterisk  is  the  off-­‐‑resonance  profile  of  A22-­‐‑C8  that  was  poorly  
fitted  to  the  two-­‐‑state  Laguerre  equation  (Eq.1)  and  likely  to  be  a  noise   in  R1ρ  values.  
Error   bars   represent   experimental   uncertainty   (one   s.d.)   as   determined   from  
propagation  of  errors  obtained  from  mono-­‐‑exponential   fitting  of  duplicate  sets  of  R1ρ  
data  and  analysis  of  signal-­‐‑to-­‐‑noise.  
 










































































































































































































































  Figure   4.4  Off-­‐‑resonance   profiles   of  R1ρ    relaxation  dispersion   in   slow   exchanging  
nuclei   in  wt  TAR.  Shown  are  dependence  of  R2   +  Rex   on   the  offsets   and   the   spinlock  
power.  The  solid  lines  denote  the  global  fits  to  the  two-­‐‑state  Laguerre  exchange  model  
(Eq.  1).  The  error  analysis  was  done  same  as  shown  in  Figure  4.3.  
  
Nuclei   R1  (Hz)   R2  (Hz)   pB  (%)   kex  (Hz)                
τ   (ms)  
Δω   (ppm)  
U23-­‐‑C6   2.50  ±0.04   30.7  ±0.1  
0.40  ±0.05  
474  ±69                    
2.1  ±0.3  
2.3  ±0.1  
U25-­‐‑C6   3.00  ±0.04   27.5  ±0.1   -­‐‑1.5  ±0.1  
A22-­‐‑C1′   1.70  ±0.02   23.8  ±0.05   -­‐‑2.2  ±0.05  
A27-­‐‑C1′   1.61  ±0.05   30.5  ±0.1   -­‐‑2.9  ±0.1  
U38-­‐‑N3   1.40  ±0.03   6.2  ±0.03   -­‐‑5.2  ±0.2  
G33-­‐‑C1′   1.93  ±0.07   21.9  ±0.1   2.4  ±0.1  
G33-­‐‑C8   2.56  ±0.10   34.1  ±0.1   2.5  ±0.1  
A35-­‐‑C8   2.13  ±0.02   18.5  ±0.04   -­‐‑2.4  ±0.04  
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The  similar  slow  exchange  parameters  observed  for  residues   in   the  apical   loop,  
upper   stem,   bulge,   and   lower   stem   could   potentially   reflect   a   common   transition  
toward   an   excited   state   that   requires   simultaneous   and   concerted   changes   in   the  
structure   of   the   bulge,   upper   stem,   and   apical   loop.   To   test   this   hypothesis,   we  
examined   the   impact   of   omitting   the   bulge   on   relaxation   dispersion  measured   in   the  
apical  loop  (TAR-­‐‑Δbulge,  Figure  4.5A).  As  expected,  omitting  the  bulge  had  no  effect  on  
the  fast  exchange  process  in  the  apical  loop,  since  ES1  involve  localized  changes  in  base-­‐‑
pairing  within  the  apical  loop  itself.  However,  omitting  the  bulge  completely  quenched  
the  slow  exchange  process  at  G33-­‐‑C8,  G33-­‐‑C1ʹ′,  and  A35-­‐‑C8,  which  are  four  base-­‐‑pairs  
away  (Figure  4.5B).  Thus,  omitting  the  bulge  specifically  quenches  the  slow  processes  at  
G33-­‐‑C8,  G33-­‐‑C1ʹ′  and  A35-­‐‑C8  without  affecting  the  fast  process  at  A35-­‐‑C1ʹ′   in  the  same  
residue   (Figure   4.5B).   Therefore,   the   slow   exchange   observed   in   the   apical   loop   is  
dependent   on   the   TAR   bulge.   Inversely,   replacing   the   wild-­‐‑type   (wt)   TAR  
hexanucleotide   apical   loop   with   a   UUCG   tetraloop   (TAR-­‐‑UUCG,   Figure   4.5A)  
completely   quenched   the   relaxation   dispersion   observed   in   the   bulge   and   the   upper  
stem   (A22-­‐‑C1ʹ′,   U23-­‐‑C6,   A27-­‐‑C1ʹ′   and   U38-­‐‑N3,   Figure   4.5C)   indicating   that   the   slow  






Figure  4.5  Co-­‐‑dependence  of  slow  relaxation  dispersion  in  the  TAR  bulge  and  apical  
loop.   A.  Constructs   used   to   independently   delete   the   TAR   bulge   (TAR-­‐‑Δbulge)   and  
replace   the   wt   apical   loop   (TAR-­‐‑UUCG).   B.   Deleting   the   TAR   bulge   selectively  
quenches  slow  exchange  in  the  TAR  apical  loop  without  affecting  fast  exchange.  Error  
bars   represent  experimental  uncertainty   (one   s.d.)   as  determined   from  propagation  of  
errors  obtained  from  mono-­‐‑exponential  fitting  of  duplicate  sets  of  R1ρ  data  and  analysis  
of   signal-­‐‑to-­‐‑noise.  C.  Replacement  of   the  wt  TAR  apical   loop  with  a  UUCG  quenches  
slow  relaxation  dispersion  in  the  bulge  and  the  upper  stem.  Error  bars  were  determined  
as  mentioned  in  B.  
  
Structure  of  HIV-­‐‑1  TAR  transient  state  by  secondary  structure  prediction  and  mutate-­‐‑
and-­‐‑chemical-­‐‑shift-­‐‑fingerprinting    
The   two-­‐‑state   analysis   of   the   off-­‐‑resonance   relaxation   dispersion   data   yields  
chemical  shifts  data   for   the   transient  state,  which  carry   important  clues  about   the  ES2  
structure.  The  ES2  carbon  chemical  shifts  can  be  converted  into  recently  formulated  H-­‐‑
factors(54)   which   measure   deviations   away   from   canonical   Watson-­‐‑Crick   geometry  
toward  non-­‐‑canonical  geometry  and  which  can  be  used  to  aid  analysis  and  visualization  
of  excited  state  carbon  chemical  shifts.  The  H-­‐‑factor  ranges  between  0  -­‐‑  68  for  residues  
that  are  the  most  to  the  least  similar  to  a  WC  geometry  respectively  (Figure  4.6).  A  few  
of  the  ES2  chemical  shifts  from  the  R1ρ  data  (Δω)  and  the  corresponding  H-­‐‑factors  were  
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strongly  suggests   the  absence  of  WC  hydrogen  bonding  to  U38-­‐‑N3H3  in  ES2  possibly  
due  to  formation  of  a  non-­‐‑canonical  base-­‐‑pair  with  distinct  h-­‐‑bonding  or  loss  of  any  h-­‐‑
bonding   to  U38-­‐‑N3(48)   (Figure  4.7A).  The  upfield   shifted  base   resonances   for  U25-­‐‑C6  
(1.5   ppm)   and   A35-­‐‑C8   (2.4   ppm)   and   correspondingly   lower   H-­‐‑factors   suggest  
increased  base-­‐‑stacking(55)   in  ES2,  while   the  downfield  shifted  U23-­‐‑C6  (2.3  ppm)  and  
increased   H-­‐‑factor   suggest   a   base-­‐‑flipped-­‐‑out   conformation(55)   (Figure   4.7A).   The  
upfield   shifted   A22-­‐‑C1ʹ′   (2.2   ppm)   and  A27-­‐‑C1ʹ′   (2.9   ppm)   suggest   sugar   repuckering  
toward   the  C2ʹ′-­‐‑endo   conformation.   Finally,   the   down-­‐‑field   shifted  G33-­‐‑C1ʹ′   (2.4   ppm)  
and  G33-­‐‑C8  (2.5  ppm)  and  increased  H-­‐‑factor  strongly  suggest  a  syn  G33  base(56),  and  
is   consistent   with   a   syn   G   involved   in   a   trans-­‐‑wobble   G-­‐‑U   base-­‐‑pair,   as   observed   in  
closing   base-­‐‑pairs   of   apical   loops   such   as   UUCG(57)   and   the   UGGG   apical   loop(20)  
observed  in  the  TAR  ES1  state.  
  
Figure  4.6  H-­‐‑factor  analysis  of  wt  TAR  chemical  shifts  and  ES2  chemical  shifts  from  



























































































circles   on   the   residues   showing   increased   (red)   or   decreased   (blue)   H-­‐‑factor   upon  
transition  into  ES2.  The  bar  graph  of  H-­‐‑factor  on  each  residue  is  also  shown.  Note  that  
except   for   3   base-­‐‑pairs   at   the   terminus,   gray   residues   (C24,  U40,  C41)  were   excluded  




Figure   4.7   Trapping   a   candidate   structure   for   the  HIV-­‐‑1   transient   state.   A.   Ground  
state   secondary   structure   of   HIV-­‐‑1   TAR.   Chemical   shift   fingerprints   indicating  
increased  stacking  and/or  anti  glycosidic  angles,  loss  of  hydrogen  bonds,  and  C2'ʹ-­‐‑endo  
sugar  pucker  are  in  blue;  decreased  stacking  and/or  syn  glycosidic  angles,  and  C3'ʹ-­‐‑endo  
sugar  pucker  are  in  red.  Sites  with  little  to  no  or  too  fast  exchange  are  in  grey.  The  sites  
at  which  the  exchange  cannot  be  measured  due  to  spectral  overlap  are  in  black.  B.  HIV-­‐‑
1   TAR   secondary   structures   predicted   using  MC-­‐‑Fold.   The   structure   that   best   agrees  
with   the   R1ρ   data   is   highlighted   in   star.  C.   Comparison   of   2D   C6/C8-­‐‑H6/H8   HSQC  
spectra  of  TAR-­‐‑G28U  and  wt  TAR.  The  assignments  with  question  marks  are  tentative  
assignments.  D.   Example   imino   proton   NOE-­‐‑connectivity   that   support   the   proposed  
secondary   structure   for   TAR-­‐‑G28U.   E.   Chemical   shift   fingerprinting.   Shown   are   the  
differences   in   chemical   shifts   determined   using   relaxation   dispersion   between   the  
ground  and  transient  state  (in  red)  with  the  corresponding  differences  in  chemical  shifts  
obtained  from  comparing  resonances  in  TAR-­‐‑G28U  (in  blue)  and  the  ground  state  of  wt  
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We   previously   showed   that   secondary   structure   prediction   programs   such   as  
MC-­‐‑Fold  can  help  identify  RNA  excited  states(20).  MC-­‐‑Fold  correctly  predicts  the  HIV-­‐‑
1   TAR   GS   and   ES1   (structures   #1   and   #2,   Figure   4.7B)   as   the   first   and   second  most  
energetically  favorable  secondary  structures.  The  next  energetically  favorable  structures  
#3-­‐‑#5   involve   changes   in   either   the   apical   loop   (#3   and   #4)   or   bulge   (#5)   without  
affecting   the   upper   stem.   Strikingly,   the   very   similar   structures   #6   and   #7   feature  
simultaneous  changes   in   the  bulge,  upper   stem,  and  apical   loop  without  affecting   the  
lower  stem,  which  show  little  signs  of  relaxation  dispersion.  This  is  accomplished  by  a  
global   change   in   the   register   of   bulge   residues   C24   and   U25,   which   pair   up   with  
residues  in  the  upper  stem  and  result  in  reshuffling  of  base-­‐‑pairs  that  propagates  to  the  
apical  loop  through  creation  of  non-­‐‑canonical  base-­‐‑pairs.    
Between   the   two  structures,   structure  #7  better   explains   the  decreased   stacking  
for   U23   and   increased   stacking   for   U25   observed   in   ES2   (Figure   4.7B).   The   non-­‐‑
canonical  U25-­‐‑U38   base-­‐‑pair   can   help   explain   the   unusual   upfield   shifted  U38-­‐‑N3   as  
well  as   increased  base-­‐‑stacking  of  U25   in  ES2   (Figure  4.7B).  G26  and  A27  retain  base-­‐‑
pairing   in   ES2   as   in   GS,   consistent   with   the   lack   of   significant   relaxation   dispersion  
measured   at   these   sites.   Formation   of   the   G28-­‐‑A35   mismatch   can   help   explain   the  
increased  base-­‐‑stacking  at  A35  in  ES2.   Importantly,  both  structures  #6  and  #7  position  
G33  at   the  apical   loop  closing  base-­‐‑pair  where   it  can   form  the  G(syn)-­‐‑  C   trans-­‐‑wobble  
base   pair   and   explaining   the   strongly downfield   shifted   G33-­‐‑C8   and   G33-­‐‑C1ʹ′.   A  
transition  toward  structures  #6  or  #7  would  minimally  require   the  opening  of  a  stable  
canonical  A27-­‐‑U38  base-­‐‑pair,  consistent  with  the  measured  activation  free  energy  (16.8  
kcal/mol;  See  Thermodynamic  analysis  in  Methods),  which  is  comparable  to  the  energy  
needed   to  open  RNA  WC  base-­‐‑pairs(58)   (13-­‐‑16  kcal/mol).  This  helps   explain  why   the  
108  
  
transition   (kex   ~   474   Hz)   is   slower   than   that   observed   for   ES1   (kex   ~   25   kHz),   which  
requires  disruption  of  the  weaker  cross  stranded  G34-­‐‑C30  base-­‐‑pair.    
  
Testing   the   proposed   HIV-­‐‑1   TAR   Transient   State   using   Mutate-­‐‑and-­‐‑chemical-­‐‑shift-­‐‑
fingerprinting  
We   used   a   ‘Mutate-­‐‑and-­‐‑Chemical   Shift-­‐‑Fingerprint’   (MCSF)   strategy(20)   to   test   the  
proposed  HIV-­‐‑1  TAR  RNA   transient   sate.   In   particular,  we   introduced   a  G28U  point  
mutation   targeting   the   center   of   the   upper   stem   that   is   predicted   by   MC-­‐‑Fold   to  
stabilize   structures   #6   and      #7   by   replacement   of   a   non-­‐‑canonical   G28-­‐‑A35   base-­‐‑pair  
with  a  more  stable  canonical  U28-­‐‑A35  base-­‐‑pair  (TAR-­‐‑G28U,  Figure  4.7C).  This  mutant  
was   chosen   among   many   options   because   it   minimizes   the   stabilization   of   other  
potentially   competing   low  energy   states   and  because   it   avoids   changing  key   residues  
that  are  used  as  chemical  shift  reporters.    
The   G28U   point   mutation   resulted   in   large   changes   in   TAR   chemical   shifts  
including   residues   in   the   lower   stem   (A22),   bulge   (U23,  U25),  upper   stem   (A27,  U38)  
and   apical   loop   (G33,   G34,   A35),   consistent   with   stabilization   of   an   alternative  
conformation  (Figure  4.7C  and  Figure  4.8).  NMR  spectra  confirmed  that  the  TAR-­‐‑G28U  
adopts   the   secondary   structure   predicted   for   structure   #7.   For   example,   we   observe  
unique   imino   resonances   and  NOE   connectivity   that   establish   formation   of   the   non-­‐‑
canonical  U25-­‐‑U38  base  pair  and  G36-­‐‑A27  mismatch  (Figure  4.7D).  We  also  observe  the  
expected   NOE   connectivity   involving   non-­‐‑exchangeable   protons   (G17-­‐‑H8   to   A22-­‐‑
H8/H1ʹ′)   that  are   interrupted  at  U23,   consistent  with  U23   rather   than  C24   forming   the  
bulge,  as  predicted  by  structure  #7.  We  also  observe  a  strong  H8/H1ʹ′  NOE  that  confirms  
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G33   adopts   a   syn   conformation   along  with   the   very   strongly   upfield   shifted  G34-­‐‑H1ʹ′  
resonance   (Figure  4.8)  which   is   characteristic  of   residues  3ʹ′-­‐‑adjacent   to   syn  G  at   tip  of  
apical   loops  engaged   in   trans-­‐‑wobble  base-­‐‑pairs   (e.g.  G(syn)-­‐‑U   in  cUUCGg   tetraloop).  
This  suggests  that  G33  likely  forms  a  trans-­‐‑wobble  with  C30.  These  results  suggest  that  
the  G28U  mutation  slightly  favor  the  structure  #7  over  structure  #6  and  strongly  favor  
structures  #6  and  #7  over  all  other  structures  (#1  -­‐‑  #5).  As  expected,  the  mutation  causes  
minimal   perturbations   to   chemical   shifts   of   the   lower   stem   residues   (G17,   G18,   A20,  
G21,  U40,  U42,  G43,  and  C45,  Figure  4.7C  and  Figure  4.8).    
  
Figure  4.8  C1ʹ′-­‐‑H1ʹ′ ,   imino  N-­‐‑H,  and  C2-­‐‑H2  HSQC  spectra  of  wtTAR  (red)  and  TAR-­‐‑
G28U  (blue).  The  assignments  with  question  marks  are  tentative  assignments.  
  
For  all  eight  resonances  showing  signs  of  slow  exchange  (A22-­‐‑C1ʹ′,  U23-­‐‑C6,  U25-­‐‑
C6,  A27-­‐‑C1ʹ′,  G33-­‐‑C8,  G33-­‐‑C1ʹ′,  A35-­‐‑C8,  and  U38  N3),  we  observe  very  strong  agreement  
between  the  carbon  and  nitrogen  chemical  shifts  measured  in  TAR-­‐‑G28U  and  the  ES2  
chemical  shifts  (Δω)  deduced  by  relaxation  dispersion  (Figure  4.7E).  The  slightly  poorer  
agreement  (~1.5  ppm)  observed  for  the  magnitude  (but  not  direction)  of  perturbations  

























































































at   A22-­‐‑C1ʹ′,   U23-­‐‑C6,   U25-­‐‑C6,   and  A27-­‐‑C1ʹ′   can   also   be   explained   by   proximity   to   the  
mutated   site   (A27-­‐‑C1ʹ′)   and   susceptibility   to   exchange   contributions   (A22-­‐‑C1ʹ′,  U23-­‐‑C6  
and   U25-­‐‑C6)   with   structure   #6   that   may   be   absent   or   modified   in   TAR-­‐‑G28U   as  
compared  to  wt  TAR.  Note  that  while  we  were  not  able  to  obtain  specific  assignments  
for  G33-­‐‑C8,  and  G33-­‐‑C1ʹ′  due  to  severe  spectral  overlap  in  TAR-­‐‑G28U,  we  were  able  to  
tentatively   assign  G33  using  NOE  walk  and  HCN   from  G34.  The  G33   resonances   fall  
downfield  (by  2.4ppm,  and  3.0ppm,  respectively)  of  wt  TAR  resonances  consistent  with  
the  ES2  carbon  chemical  shifts  (2.5  ppm  and  2.4  ppm,  respectively)  for  these  resonances  
obtained  by  relaxation  dispersion  (Figure  4.7E).    
Importantly,   residues   that   show   little   or   no   sign   of   relaxation   dispersion   also  
show  small  differences  in  carbon  or  nitrogen  chemical  shifts  (typically  <0.5  ppm)  when  
comparing  wt  TAR  and  TAR-­‐‑G28U,  including  G21-­‐‑C1ʹ′,  A22-­‐‑C8,  U23-­‐‑C1ʹ′,  A27-­‐‑C2,  G32-­‐‑





Figure  4.9  Off-­‐‑resonance  profiles  of  R1r  relaxation  dispersion  and  the  chemical  shift  
fingerprints  of  the  residues  that  did  not  show  relaxation  dispersion.  
  
Deconvoluting   ES1   and   ES2   relaxation   dispersion   contributions   through   temperature  
dependencies  
Given  that  transitions  to  ES1  and  ES2  entail  very  different  timescales,  one  might  
wonder  why  certain  apical  loop  residues  do  not  sense  both  ES1  and  ES2,  and  therefore  
necessitate  a  3-­‐‑state  rather  than  2-­‐‑state  fit  to  the  dispersion  data.  For  many  resonances,  
the  differences  in  chemical  shifts  between  GS  and  ES  (Δω)  are  expected  to  be  significant  
only  for  one  of  the  two  ESs.  For  example,  based  on  comparison  of  spectra  for  wt  TAR  
and  trapped  mutants  of  ES1  and  ES2,  the  differences  in  chemical  shifts  for  A35-­‐‑C1ʹ′  are  
expected  to  be  1.3  ppm  and  0  ppm  for  ES1  and  ES2  (Figure  4.8),  respectively.  Likewise,  
for  G34-­‐‑C8,  the  differences  in  chemical  shifts  are  expected  to  be  1.8  and  0  ppm  for  ES1  

























































































































and  ES2  (Figure  4.7C),  respectively.  For  other  sites  in  the  apical  loop  (C30-­‐‑C1ʹ′,  U31-­‐‑C1ʹ′,  
and  G34-­‐‑C1ʹ′),   it   is  possible   that   any   relaxation  dispersion   contributions  due   to  ES2   is  
masked   by   greater   relaxation   dispersion   contributions   due   to   ES1.   Indeed,   the  
simulations  of  relaxation  dispersion  on  these  resonances  using  3-­‐‑state  model  (ES1  ßà  
GS  ßà  ES2)  show  that  the  effective  transverse  relaxation  rate  constant  with  chemical  
exchange  (R2  +  Rex)  from  the  low  populated  ES2  is  completely  masked  by  the  effective  
transverse   relaxation   rate   constant   from   ES1  which   has   higher   population   and   faster  
exchange  rate  constant  (data  not  shown).  The  relaxation  rate  constant  due  to  chemical  
exchange  of  ES1  (Rex  ~  17  -­‐‑  21  Hz)  is  approximately  2-­‐‑3  times  higher  than  that  of  ES2  (Rex  
~  5  -­‐‑  10  Hz)  and  if  the  chemical  shift  differences  (Δω)  of  these  resonances  in  ES1  and  ES2  
from  the  ground  state  are  also  similar   in  direction,   the  relaxation  dispersion  profile  of  
ES2  is  highly  likely  masked  by  that  of  ES1.    
To  detect  slow  exchange  to  ES2  that  may  be  masked  by  fast  exchange  to  ES1,  we  
performed  relaxation  dispersion  experiments  at  a  higher  temperature  of  35ºC,  where  we  
expect  to  push  the  already  very  fast  process  involving  ES1  outside  the  limit  of  detection  
by   the  R1ρ   relaxation  dispersion   experiment.  As   expected,   all   residues   showing   slow  
exchange   due   to   ES2   at   25ºC   also   exhibited   slow   exchange   at   35ºC   (Figure   4.10   and  
Table  4.2)  yielding  similar  population  (pB  =  ~0.2  %),  ES2  chemical  shifts,  and  as  expected  
increased  exchange  rate  constants  (kex  =  ~2100  Hz)  compared  to  those  measured  at  25ºC.    
Among  the  apical  loop  residues  showing  signs  of  fast  exchange,  G34-­‐‑C8  and  A35-­‐‑C1ʹ′  no  
longer  showed  signs  of  relaxation  dispersion  at  35ºC  (Figure  4.11A)  indicating  that  the  
fast   exchange   process   is   now   outside   the   limit   of   detection   and   that   any   changes   in  
chemical   shifts   accompanying   formation   of   ES2   are   small   –   this   was   later   confirmed  




Figure  4.10  Off-­‐‑resonance  profiles  of  R1ρ   relaxation  dispersion  at  35  oC  
     





























































































































































Nuclei   R1  (Hz)   R2  (Hz)   pB  (%)  
kex  (Hz)                    
τ   (ms)  
Δω   (ppm)  
U23-­‐‑C6   2.82  ±0.05   23.0  ±0.1  
0.24  ±0.01  
2131  ±96                
0.47  ±0.02  
2.0  ±0.1  
U25-­‐‑C6   2.97  ±0.03   19.0  ±0.1   -­‐‑1.9  ±0.1  
A22-­‐‑C1′   2.02  ±0.03   17.2  ±0.1   -­‐‑1.8  ±0.1  
A27-­‐‑C1′   1.58  ±0.04   23.4  ±0.1   -­‐‑2.2  ±0.1  
U38-­‐‑N3   1.90  ±0.08   5.7  ±0.1   -­‐‑5.2  ±0.3  
G33-­‐‑C1′   1.98  ±0.06   15.3  ±0.1   1.9  ±0.1  
G33-­‐‑C8   2.26  ±0.02   21.7  ±0.1   2.0  ±0.1  
A35-­‐‑C8   2.06  ±0.02   11.3  ±0.04   -­‐‑2.2  ±0.1  
C30-­‐‑C1′   2.11  ±0.03   25.6  ±0.1   1.9  ±0.1  
G34-­‐‑C1′   2.15  ±0.04   22.6  ±0.1   2.9  ±0.1  
U31-­‐‑C1′   2.34  ±0.03   18.7  ±0.1   1.3  ±0.1  





Figure   4.11   R1ρ    relaxation   dispersion   of   apical   loop   ES1   nuclei   at   35   oC.   A.   Off-­‐‑
resonance   profiles   of   C30-­‐‑C1ʹ′,   U31-­‐‑C1ʹ′,   A35-­‐‑C1ʹ′,   G34-­‐‑C1ʹ′,   and   G34-­‐‑C8.   Shown   are  
global   fits   (solid   line)   to   a   two-­‐‑state   Laguerre   exchange   model   (Eq.   1).   Error   bars  
represent  experimental  uncertainty  (one  s.d.)  as  determined  from  propagation  of  errors  
obtained   from  mono-­‐‑exponential   fitting   of   duplicate   sets   of   R1ρ   data   and   analysis   of  
signal-­‐‑to-­‐‑noise.  B.  Chemical  shift   fingerprinting  of  nuclei  showing  dispersion  at  35  oC.  
The  color  scheme  is  same  as  in  Figure  4.9.  
    
By   contrast,   resonances   belonging   to   C30-­‐‑C1ʹ′,   U31-­‐‑C1ʹ′,   and   G34-­‐‑C1ʹ′   which  
exhibit  signs  of  fast  exchange  at  25ºC  unexpectedly  start  to  exhibit  slow  exchange  (kex  =  
1552  –  2666  Hz)  at  higher  temperature  of  35ºC  (Figure  4.11A)  that  are  directed  toward  a  
lower  populated  (pB  ~  0.2  %)  transient  state.  These  exchange  rates  and  populations  are  
in   excellent   agreement  with   those   attributed   to   ES2   at   35ºC   (Table   4.2).   For   example,  
G34-­‐‑C1ʹ′   of   TAR-­‐‑G28U   shows   3.5ppm   downfield   shift   from   that   of   wt   TAR,   which  
agrees  well  with   the  ES2   carbon   chemical   shift   (2.9  ppm)   from   the  dispersion  data   at  
35ºC,   which   is   consistent   with   G34-­‐‑C1ʹ′   being   adjacent   to   G33(syn)-­‐‑C30   trans-­‐‑wobble  















































































































































base   pair   (Figure   4.11B).   Likewise,   G34-­‐‑C8   and   A35-­‐‑C1ʹ′,   which   no   longer   shows   the  
relaxation  dispersion  at  35ºC,  have  identical  carbon  chemical  shifts  between  TAR-­‐‑G28U  
and  wt  TAR   (Figure   4.7C   and  Figure   4.8).  Again,  we  were  not   able   to   obtain   specific  
assignments  for  C30-­‐‑C1ʹ′  and  U31-­‐‑C1ʹ′  due  to  severe  spectral  overlap  in  TAR-­‐‑G28U  but  
are   tentatively   assigned   by   HCN   and   TAR-­‐‑UUCG   spectra(59)   which   has   similar  
tetraloop  to  the  TAR-­‐‑G28U.  The  C30-­‐‑C1ʹ′  and  U31-­‐‑C1ʹ′  shift  downfield  (by  2.7  ppm  and  
0.6  ppm,   respectively)  of  wt  TAR  resonances  consistent  with   the  ES2  carbon  chemical  
shifts  for  these  resonances  obtained  by  relaxation  dispersion  at  35ºC,  all  of  which  shift  
downfield   relative   to   the   GS   by   1.9ppm   and   1.3ppm,   respectively   (Figure   4.11B).  
Although  the  data  is  more  noisy  than  that  measured  at  25oC  possibly  due  to  lower  ES2  
population  at  35ºC  (Figure  4.10  and  Figure  4.11A),  global  fitting  of  the  dispersion  data  
measured  at  35ºC  (Table  4.2)  allowed  us  to  deduce  the  ES2  chemical  shifts  belonging  to  
C30-­‐‑C1ʹ′,  U31-­‐‑C1ʹ′,  and  G34-­‐‑C1ʹ′  which  are  otherwise  masked  by  the  fast  exchange  to  ES1  
at  25ºC.    
Functional  significance  of  TAR  ES2  
Correlated   exchange   at   the   apical   loop   and   bulge   provides   a   basis   for   long-­‐‑range  
allosteric   communication   in   HIV-­‐‑1   TAR.   To   test   this   possibility,   we   examined   how  
binding  of  argininamide  (ARG)  -­‐‑  a  ligand  mimic  of  TAR’s  cognate  protein  target  Tat  -­‐‑  to  
the  TAR  bulge  affects  dispersion  measured  in  the  apical  loop.  Previous  NMR  studies(36,  
60,  61)  showed  that  ARG  binds  HIV-­‐‑1  TAR  in  and  around  the  bulge  stabilizing  a  coaxial  
conformation  in  which  bulge  residues  U23  forms  reverse  Hoogsteen  with  the  A27-­‐‑U38  
base-­‐‑pair  in  the  upper  stem.  If  our  proposed  transient  state  is  correct,  one  would  expect  
that  ARG  binding  would  quench  chemical  exchange  due  to  ES2  because  by  locking  the  
bulge   conformation,   the  ARG   bound   state   is   incapable   of   forming   ES2   conformation.  
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Indeed,  addition  of  16-­‐‑fold  ARG  (11  mM)  to  TAR  quenched  the  relaxation  dispersion  at  
the   slow   exchanging   sites   in   the   apical   loop   (G33-­‐‑C8   and   A35-­‐‑C8,   Figure   4.12).  
Interestingly,  ARG  binding  also  quenched  relaxation  dispersion  at  sites  associated  with  
fast  exchange  to  ES1  (U31-­‐‑C1ʹ′  and  G34-­‐‑C8).  Prior  studies  have  shown  that  ARG  binding  
affects  the  chemical  exchange  at  TAR  apical  loop  resonances  undergoing  fast  exchange  
and   this   was   attributed   to   a   secondary   ARG   binding   site(62).   Evidence   for   two   or  
possibly  more  ARG  binding  sites  in  TAR  was  also  previously  obtained  using  the  surface  
plasmon  resonance  experiments(63).  Although  we  cannot  rule  out  that  binding  of  ARG  
to  the  apical   loop  is  the  cause  of  quenching  dispersion  at  slow  exchanging  sites,  other  
data   showing   that   omission   of   the  TAR  bulge   quenches  dispersion   at   the   apical   loop  
strongly   suggests   that   binding   to   the   bulge   allosterically   quenches   slow   millisecond  




Figure   4.12   R1ρ    relaxation   dispersion   profiles   of   wt   TAR   bound   to   ARG.  The   off-­‐‑
resonance  profiles  depict   the  relaxation  dispersion  of  ES2  nuclei   (G33-­‐‑C8  and  A35-­‐‑C8)  
and   the   on-­‐‑resonance   profiles   depict   the   relaxation   dispersion   of   ES1   nuclei   (G34-­‐‑C8  
and  U31-­‐‑C1ʹ′).   Error   bars   represent   experimental   uncertainty   (one   s.d.)   as   determined  
from  propagation  of  errors  obtained  from  mono-­‐‑exponential  fitting  of  duplicate  sets  of  
R1ρ  data  and  analysis  of  signal-­‐‑to-­‐‑noise.  
  
One  of  the  unique  features  of  TAR  is  that  it  is  capable  of  binding  to  wide  variety  
of   proteins   that   are   thought   to   interact   with   the   TAR   bulge   and/or   apical   loop.      For  
example,  the  protein,  Tat,  is  thought  to  primarily  bind  to  the  TAR  bulge(64)  whereas  the  
proteins   TAR   RNA   binding   protein   (TRBP)(65)   and   possibly   RNA-­‐‑activated   protein  




































































kinase  (PKR)(66)  are  thought  to  also  interact  with  apical  loop.  It  is  possible  that  some  of  
these  proteins  recognize  ES2  or  ES1  forms  of  TAR.  The  ES2  may  also  help  explain  prior  
data   showing   evidence   for   long-­‐‑range   functional   communication   between   the   TAR  
bulge  and  apical  loop.  This  includes  the  cooperative  binding  of  cyclin  T1-­‐‑Tat  complex  to  
TAR  bulge  and  the  apical  loop(44),  elusive  correlated  motions  between  U31  of  the  apical  
loop  and  the  U23  and  C24  of  the  bulge(67),  and  a  small  molecule  achieving  high  affinity  
and   specificity   to  TAR  by   targeting   the  bulge  and   the  apical   loop   simultaneously(37).  
Indeed,  among  3166  full-­‐‑length  TAR  sequences  obtained  from  HIV  sequence  database  
(http://www.hiv.lanl.gov/),  850  non-­‐‑redundant  sequences  were  subject  to  the  secondary  
structure   prediction   by   MC-­‐‑fold.   Among   them,   627   sequences   were   predicted   to  
support  ES2  (data  not  shown).  Therefore,  the  ES2  seemed  to  be  highly  conserved  (74%)  
among  the  HIV-­‐‑1  strains,  implying  its  significant  involvement  in  the  viral  life  cycle.    
  
4.4 Conclusion  
In   the  present   study,  we  have  characterized   the  slowly  exchanging  state,  ES2,   (τ   =  2.1  
ms;   pB   =   0.4%)   of   TAR  using  R1ρ relaxation   dispersion.  Unlike   the   ES1   structure   that  
involved  local  base-­‐‑pair  arrangements  restricted  in  the  apical  loop,  the  ES2  involved  the  
bulge,   upper   stem,   and   the   apical   loop   residues   rearranged   to   form   a   more   helical  
conformation.   We   have   also   shown   that   by   increasing   temperature,   the   slowly  
exchanging  state  can  be  isolated  from  the  fast  exchanging  state  which  otherwise  hid  the  
slow  exchange  process.  Based  on   the  R1ρ  measurements  at  high   temperature,   the  ES1  
and  ES2  may  be  independent  of  each  other,  but  we  could  not  rule  out  the  possibility  of  
the  exchange  process  between  ES1  and  ES2  (Figure  4.13).   It   is  also  unclear  how  ES2  is  
involved  in  the  HIV-­‐‑1  life  cycle,  but  we  showed  that  the  ES2  is  highly  conserved  in  the  
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HIV-­‐‑1   strains   and   hinted   that   the   ES2   likely   involve   with   an   allosteric   regulatory  
mechanism.   Nonetheless,   our   study   experimentally   characterized   the   long-­‐‑range  
correlation   between   the   bulge   and   the   apical   loop   of   TAR   and  may   provide   further  
insights  into  the  transient  structures  within  RNA.  
  
Figure   4.13   Proposed   µs   –   ms   exchange   model   in   TAR.   Shown   are   the   secondary  
structures  of  ES1  and  ES2  with   lifetime   (τ),   forward   rate   constants   (k1)   and  backward  
rate   constants   (k-­‐‑1)   calculated   from   their   exchange   rate   constants   (kex   =   k1   +   k-­‐‑1)   and  
population  (pB).    
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Conclusions  and  Future  Directions  
5.1 Conclusions  and  Future  Directions  
Despite   non-­‐‑coding   RNAs   being   attractive   therapeutic   targets   and   much   effort  
directed   toward   targeting   RNA   with   small   molecules   to   modulate   the   regulatory  
functions,   there  has  not  been  novel  drugs   that  have  been  discovered   that   target  RNA  
other   than   the   well-­‐‑known   aminoglycoside   antibiotics   that   target   ribosomes.   This  
dissertation   examined   the   feasibility   of   using   experimental   and   virtual   screening  
approaches  to  identify  small  molecules  that  bind  RNA.    
In  Chapter  2,  we  investigated  the  influence  of  dimethyl  sulfoxide  (DMSO)  on  RNA  
structure,  dynamics,   and   ligand  binding  using   fluorescence  binding   assays   and  NMR  
spectroscopy.  We  showed  that  DMSO  (up  to  10%  DMSO  by  volume)  locally  melts  the  
junctions  that  connect  RNA  helices  such  as  bulge  in  HIV-­‐‑1  TAR  and  internal  loop  in  16S  
ribosomal   A-­‐‑site.   The   binding   affinities   of   positively   charged   compounds   such   as  
argininamide,   and   kanamycin,   did   not   show   significant   changes   in   DMSO,   but  
mitoxantrone  which  binds  TAR  and  A-­‐‑site  via  intercalation  notably  showed  3  –  4-­‐‑fold  
reduced   binding   affinity.   While   the   effect   of   DMSO   on   ligand   binding   was   not  
significant   compared   to   prior   studies   on   protein-­‐‑ligand   complexes   (1),      the   RNA  
structural  changes  induced  by  DMSO  deserve  careful  attention  before  proceeding  with  
ligand  binding  assays  and  high  throughput  screening  campaigns.    
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Future   studies   should   examine   how   DMSO   affects   the   structure,   dynamics   and  
folding  behavior  of  RNA  containing  deep  binding  pockets  such  as  the  aptamer  domains  
of  RNA  riboswitches.  The   influence  of  DMSO  may  differ   from   that  observed  here   for  
hairpin   structures  with  more   solvent-­‐‑exposed  binding  pockets.   Future   studies   should  
also  examine  how  other  organic  solvents  affect  RNA  behavior  to  more  fully  understand  
the  origin  of  the  DMSO  effect.      
In   Chapter   3,   we   embarked   on   the   high   throughput   screening   (HTS)   and   the  
ensemble-­‐‑based  virtual  screening  (VS)  of  ~100,000  small  molecules  targeting  HIV-­‐‑1  TAR  
in  order  to  find  novel  inhibitors  as  well  as  compare  the  performance  of  HTS  and  the  VS.  
This  provided  the  first  opportunity  to  comprehensively  assess  the  performance  of  RNA-­‐‑
targeted  VS.  We   showed   that   the   two   techniques   are   complimentary   to   one   another,  
yielding   different   classes   of   small   molecule   hits.   Furthermore,   we   showed   the  
importance  of  working  with  an  unbiased  small  molecule  library  when  assessing  the  VS  
approach.  With   this   approach  we  were   able   to   identify   total   11  novel   small  molecule  
hits,  one  of  which  showed  activity  in  the  cell-­‐‑based  assays  using  T-­‐‑cell  lines  and  TZM-­‐‑bl  
reporter  cell  lines.    
Future  studies  should  examine  how  the  quality  of  ensembles  affect  the  performance  
of  the  VS.  In  particular,  the  current  ensemble  used  in  the  VS  contained  RDCs  targeting  
the   helices   and   bulge;   a   new   ensemble   should   be   tested   in   which   RDCs   are   also  
measured   targeting   the   apical   loop.   Improvements   in   the   ensemble   could   also   be  
obtained  by  using  other  experimental  constraints  in  the  ensemble  determination  such  as  
chemical   shifts.   A   key   question   is   whether   having   the   proper   representation   of   the  
unbound  solution  ensemble  leads  better  predictions  in  VS  and  whether  small  molecules  
broadly  target  conformers  within  the  ensemble  or  prefer  a  subset  of  conformations  that  
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may   have   unique   binding   pockets.   There   is   also   a   need   to   assess   various   docking  
programs   and   not   only   ICM   tested   here   to   ascertain   what   the   main   weaknesses   in  
scoring  functions  are.    Of  particular  importance  is  the  effects  of  conformational  entropy  
which  are  not   readily   captured   in   scoring   functions  and  which  can  be  experimentally  
evaluated   using   ITC   experiments.   Likewise,   there   is   a   need   to   critically   assess   pose  
predictions  obtained   form  docking.  This   can  be  done  efficiently  with   the  use  of  NMR  
chemical  shift  mapping  experiments.  On  the  experimental  side,   the  compound  106134  
showed  promising   activity.   Future   follow  up   studies   should   examine   variants   of   this  
small  molecule  to  see  if  the  activity  can  be  further  improved.  One  possibility  would  be  
to  link  the  small  molecule  with  dimethyl  amiloride  (DMA),  which  uniquely  targets  the  
TAR   apical   loop.   In   addition,   determination   of   high   resolution   structures   for   the  
compound  bound  to  TAR  by  NMR  or  X-­‐‑ray  crystallography  can  help  directing  future  
rational  modifications  of  the  small  molecule.    
In  Chapter  4,  we  have  characterized  the  second  transient  state  of  HIV-­‐‑1  TAR  using  
NMR  R1ρ   relaxation  dispersion  and  mutagenesis.  This   transient   state   involves   the   re-­‐‑
orientation   of   bases   and   base-­‐‑pairs   in   bulge,   upper   helix,   and   apical   loop   of   TAR,  
suggesting  a  long-­‐‑range  correlation  between  the  bulge  and  the  apical  loop.  Even  though  
this   transient   state   is   lowly   populated   (0.4%)   with   lifetime   of   2   milliseconds,   the  
occurrence   of   the   transient   state   in   HIV-­‐‑1   TAR   sequences   seems   highly   conserved,  
implying   that   this   transient   state   is   biologically   important.   Future   studies   should  
examine  the  exact  topology  linking  the  TAR  ground  state  and  the  two  distinct  transient  
states  that  have  been  uncovered  so  far  (2).  This  could  be  accomplished  by  carrying  out  
dispersion  measurements  as  a  function  of  pH  so  to  perturb  one  equilibrium  while  not  
affecting   the   second.   In   addition,   studies   should   be   carried   out   to   examine   the  
functional   significance   of   the   HIV   transient   state   uncovered   here.   In   particular,   cell
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based  assays  can  be  used  to  examine  how  TAR  mutants  that  favor  the  ground  state  or  
the  transient  states  affect  Tat  binding  and  transcriptional  activation.  More  broader  viral  
studies  may  make  it  possible  to  examine  the  role  of  these  transient  states  in  other  steps  
of  viral  replication.  Of  particular   interest  will  be  to  examine  whether  the  mutants  that  
trap   the   transient   states   support   transcriptional   activation   of   the   viral   genome.   Our  
secondary  structure  suggests  that  the  transient  states  do  not  have  the  requirements  for  
Tat  binding  and  consequently,  should  disfavor  transcriptional  activation.  If  this  proves  
to   be   the   case,   studies   can   be   carried   out   for   finding   small   molecules   that   target  
specifically  transient  states  of  RNA.  
The   work   presented   in   this   thesis   also   paves   the   way   for   a   new  mode   of   RNA-­‐‑
screening.   In   particular,   transient   states   of   RNA   have   sufficiently   altered   secondary  
structure   that   they  may  have  vastly  different   functions.  One  possibility   is   therefore   to  
find   small   molecules   that   specifically   target   transient   states   of   RNA.   This   can   be  
accomplished  using  two  distinct  strategies.  The  first  involves  using  mutants  to  trap  the  
transient   state   and   then   subject   the  mutants   to   conventional   HTS   and   VS.   A   second  
approach  would  involve  using  the  wild-­‐‑type  construct,  but  using  NMR  chemical  shift  
mapping  to   identify  small  molecules  that  specifically  trap  a  transient  state  as  assessed  
based  on  chemical  shift  fingerprinting.  
There   are   many   unsolved  mysteries   about   how   small   molecules   bind   RNA.   The  
most   daunting   challenge   in   RNA-­‐‑targeted   drug   discovery   is   to   find   small  molecules  
that   are   active   in   vivo   since   many   small   molecules   that   showed   activities   in   in   vitro  
biochemical  assays  failed  to  show  activities  in  in  vivo  assays.  One  hypothesis  is  that  the  
small  molecules  must  achieve  high  specificity  to  the  target  RNA  in  order  to  avoid  being  
sequestered   by   other   RNAs   in   vivo.   The   most   widely   used   RNA   for   testing   the  
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specificity   of   small   molecules   is   transfer   RNA   (tRNA)   which   is   one   of   the   most  
abundant  RNA   in   cells.  However,   the  known  antibiotics   such  as   aminoglycosides   are  
promiscuous  binders  to  a  variety  of  RNA  elements  including  tRNA,  but  yet  they  exhibit  
antibiotic   activities   in   cells   by   binding   to   a   specific   16S   ribosomal   decoding   RNA.   In  
addition,   we   have   discovered   9   inhibitors   of   TAR-­‐‑Tat   interaction   in   the   presented  
dissertation   that   showed   exquisite   specificity   against   excess   tRNA,   but   only   1   small  
molecule  showed  a  promising  activity  in  cells.  It  is  still  unclear  whether  the  specificity  
to  the  target  RNA  governs  the  in  vivo  activities  or  there  are  other  mechanisms  that  are  
active  in  cells.    
Another   question   that   needs   to   be   addressed   is  what   are   the   properties   of   small  
molecules  that  favor  RNA  binding  and  how  do  they  differ  form  protein-­‐‑binding  small  
molecules.     Because  of  differences  in  the  biophysical  and  structural  properties  of  RNA  
and  proteins,  we   can   expect   that   the  properties  of  RNA-­‐‑binding   small  molecules  will  
differ   from   those   of   protein-­‐‑binding   small   molecules.   Indeed,   many   small   molecules  
that   bind   to   RNA   including   aminoglycosidic   antibiotics   are   positively   charged   or  
contain   a   planar   aromatic   ring   that   can   be   stacked   with   nucleobases   or   intercalated  
between  the  nucleobases.  However,  the  presented  dissertation  showed  10  new  TAR-­‐‑Tat  
inhibitors  that  are  not  positively  charged  and  rarely  contain  aromatic  rings,  suggesting  
that  there  are  still  many  chemotypes  of  RNA-­‐‑binding  small  molecules  that  have  not  yet  
been   discovered.   There   is,   therefore,   a   need   to   increase   the   scale   of   RNA-­‐‑targeted  
screening  to  more  efficiently  explore  new  regions  of  small  molecule  space  and  a  variety  
of  RNA  targets.  
Targeting   RNA   with   small   molecules   is   still   challenging   but   not   impossible.  
Currently,  we  need  more  small  molecules  that  are  unique  and  bind  RNA  specifically  in  
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order  to  address  the  aforementioned  problems  and  questions.  This  dissertation  showed  
two   approaches   that   can   facilitate   the   search   for   potential   RNA-­‐‑binding   small  
molecules.   These   approaches   have   targeted   specifically   HIV-­‐‑1   TAR,   but   they   can   be  
generalized   to   target   other   therapeutic   RNAs.   In   the   next   decade,   we   can   expect   an  
expansion   in   the   chemical   space   of   RNA-­‐‑binding   small   molecules   and   our  
understanding   of  RNA-­‐‑small  molecule   interactions   and  how   small  molecules   achieve  
their  activities  in  vivo.  With  20  classes  of  non-­‐‑coding  RNAs  that  form  unique  secondary  
and  tertiary  structures,  a  universe  of  RNA-­‐‑binding  small  molecules  is  expected.    
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